<html lang="en" class="pb-page js" data-request-id="94d6373973c9f179-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6373973c9f179-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/f1cdVW9VFpIRdl325zQ93x86EMrovb4bMMMeUqFdxFmm5h0p7sthSOT_GZaz6JMArMTjHVve_AahBDPKCM0DdA=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6373973c9f179-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.4786215035013429"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="Specialties" content="Pulmonary/Critical Care">
<meta name="topics" content="COPD">
<meta name="articleCategory" content="Research"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa1916046","title":"Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD","category":"Research","type":"Original Article","topics":"COPD","specialties":"Pulmonary/Critical Care","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-07-02T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Pulmonary/Critical Care\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"COPD\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa1916046","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":{"type":"Quick Take","title":"Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD","doi":"10.1056/NEJMdo005760","issueDate":"2020-07-02T00:00Z","age":"6Months-1990","isFree":"n","topics":"COPD","viewType":"Full","specialties":"Pulmonary/Critical Care"}};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6373973c9f179-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD"><meta name="dc.Creator" content="Klaus F. Rabe"><meta name="dc.Creator" content="Fernando J. Martinez"><meta name="dc.Creator" content="Gary T. Ferguson"><meta name="dc.Creator" content="Chen Wang"><meta name="dc.Creator" content="Dave Singh"><meta name="dc.Creator" content="Jadwiga A. Wedzicha"><meta name="dc.Creator" content="Roopa Trivedi"><meta name="dc.Creator" content="Earl St. Rose"><meta name="dc.Creator" content="Shaila Ballal"><meta name="dc.Creator" content="Julie McLaren"><meta name="dc.Creator" content="Patrick Darken"><meta name="dc.Creator" content="Magnus Aurivillius"><meta name="dc.Creator" content="Colin Reisner"><meta name="dc.Creator" content="Paul Dorinsky"><meta name="dc.Description" content="Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been s..."><meta name="Description" content="Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been s..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-07-02"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa1916046"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202007023830109"><meta name="dc.Language" content="EN"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa1916046">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa1916046">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa1916046">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD | NEJM">
        <meta property="og:title" content="Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa1916046">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/7146d115-33d7-4ddc-b19a-30372b6c95cb/nejmoa1916046_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/7146d115-33d7-4ddc-b19a-30372b6c95cb/nejmoa1916046_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic
antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive pulmonary
disease (COPD) have been s...">
        <meta name="twitter:description" content="Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic
antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive pulmonary
disease (COPD) have been s...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="1816">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa1916046">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1916046">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa1916046;wgroup:string:MMS NextGen Website Group;issue:issue:doi\:10.1056/nejm_2020.383.issue-1;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1916046" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1916046" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1916046" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa1916046" class="inputDoi"><input type="hidden" value="K.F. Rabe and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;383:35-48" class="inputCitation"><input type="hidden" value="06-24-2020" class="inputEPubDate"><input type="hidden" value="July 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6373973c9f179-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Klaus F.</span> <span property="familyName">Rabe</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Fernando J.</span> <span property="familyName">Martinez</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Gary T.</span> <span property="familyName">Ferguson</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Chen</span> <span property="familyName">Wang</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Dave</span> <span property="familyName">Singh</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jadwiga A.</span> <span property="familyName">Wedzicha</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Roopa</span> <span property="familyName">Trivedi</span>, <span property="honorificSuffix">M.S.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+7</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Earl</span> <span property="familyName">St. Rose</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Shaila</span> <span property="familyName">Ballal</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Julie</span> <span property="familyName">McLaren</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Patrick</span> <span property="familyName">Darken</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Magnus</span> <span property="familyName">Aurivillius</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Colin</span> <span property="familyName">Reisner</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Paul</span> <span property="familyName">Dorinsky</span>, <span property="honorificSuffix">M.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the ETHOS Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-7</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">June 24, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">383</span></span>:<span property="pageStart">35</span>-<span property="pageEnd">48</span></div><div class="doi">DOI: 10.1056/NEJMoa1916046</div><div class="core-enumeration"><a href="/toc/nejm/383/1"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">383</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">1</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DKlaus%2BF.%2BRabe%252C%2BFernando%2BJ.%2BMartinez%252C%2BGary%2BT.%2BFerguson%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D1%26contentID%3D10.1056%252FNEJMoa1916046%26title%3DTriple%2BInhaled%2BTherapy%2Bat%2BTwo%2BGlucocorticoid%2BDoses%2Bin%2BModerate-to-Very-Severe%2BCOPD%26publicationDate%3D07%252F02%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa1916046" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DKlaus%2BF.%2BRabe%252C%2BFernando%2BJ.%2BMartinez%252C%2BGary%2BT.%2BFerguson%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D1%26contentID%3D10.1056%252FNEJMoa1916046%26title%3DTriple%2BInhaled%2BTherapy%2Bat%2BTwo%2BGlucocorticoid%2BDoses%2Bin%2BModerate-to-Very-Severe%2BCOPD%26publicationDate%3D07%252F02%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/d60f3d15-cf86-42df-841b-557bb2062255/nejmoa1916046.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa1916046.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1916046" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1916046" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1916046.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β<sub>2</sub>-agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been studied at single dose levels of inhaled glucocorticoid, but studies at two dose levels are lacking.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In a 52-week, phase 3, randomized trial to evaluate the efficacy and safety of triple therapy at two dose levels of inhaled glucocorticoid in patients with moderate-to-very-severe COPD and at least one exacerbation in the past year, we assigned patients in a 1:1:1:1 ratio to receive twice-daily inhaled doses of triple therapy (inhaled glucocorticoid [320 μg or 160 μg of budesonide], a LAMA [18 μg of glycopyrrolate], and a LABA [9.6 μg of formoterol]) or one of two dual therapies (18 μg of glycopyrrolate plus 9.6 μg of formoterol or 320 μg of budesonide plus 9.6 μg of formoterol). The primary end point was the annual rate (the estimated mean number per patient per year) of moderate or severe COPD exacerbations, as analyzed in the modified intention-to-treat population with the use of on-treatment data only.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">The modified intention-to-treat population comprised 8509 patients. The annual rates of moderate or severe exacerbations were 1.08 in the 320-μg–budesonide triple-therapy group (2137 patients), 1.07 in the 160-μg–budesonide triple-therapy group (2121 patients), 1.42 in the glycopyrrolate–formoterol group (2120 patients), and 1.24 in the budesonide–formoterol group (2131 patients). The rate was significantly lower with 320-μg–budesonide triple therapy than with glycopyrrolate–formoterol (24% lower: rate ratio, 0.76; 95% confidence interval [CI], 0.69 to 0.83; P&lt;0.001) or budesonide–formoterol (13% lower: rate ratio, 0.87; 95% CI, 0.79 to 0.95; P=0.003). Similarly, the rate was significantly lower with 160-μg–budesonide triple therapy than with glycopyrrolate–formoterol (25% lower: rate ratio, 0.75; 95% CI, 0.69 to 0.83; P&lt;0.001) or budesonide–formoterol (14% lower: rate ratio, 0.86; 95% CI, 0.79 to 0.95; P=0.002). The incidence of any adverse event was similar across the treatment groups (range, 61.7 to 64.5%); the incidence of confirmed pneumonia ranged from 3.5 to 4.5% in the groups that included inhaled glucocorticoid use and was 2.3% in the glycopyrrolate–formoterol group.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Triple therapy with twice-daily budesonide (at either the 160-μg or 320-μg dose), glycopyrrolate, and formoterol resulted in a lower rate of moderate or severe COPD exacerbations than glycopyrrolate–formoterol or budesonide–formoterol. (Funded by AstraZeneca, ETHOS ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02465567" target="_blank">NCT02465567</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo005760/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/0cb7a135-0082-4238-9a1e-f8e9e80e63c8/media/NEJMdo005760_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo005760/full/" class="ng-do-media_item-title-link">Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 24s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Treatment recommendations for chronic obstructive pulmonary disease (COPD) involve a stepwise approach, in which treatments are added as necessary to control symptoms and reduce or eliminate exacerbations,<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-1" href-manipulated="true" aria-label="Reference 1">1</a></sup> with an additional goal of reducing mortality from the disease. Triple therapy with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β<sub>2</sub>-agonist (LABA) was shown to lead to a lower risk of COPD exacerbations, a greater reduction in symptoms, and better lung function and health-related quality of life than dual therapies<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2 r3 r4 r5 r6" id="body-ref-r6-1" href-manipulated="true">2-6</a></sup> and is recommended for patients who continue to have symptoms or exacerbations while receiving dual therapy with LAMA–LABA or inhaled glucocorticoid–LABA.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-2" href-manipulated="true" aria-label="Reference 1">1</a></sup></div><div role="paragraph">Adverse events associated with inhaled glucocorticoids include pneumonia, bone fractures, and cataracts, for which the magnitude of risk may depend on the duration, dose, and type of inhaled glucocorticoid treatment.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8 r9 r10" id="body-ref-r10" href-manipulated="true">7-10</a></sup> Therefore, in a 52-week trial involving symptomatic patients with moderate-to-very-severe COPD and at least one exacerbation in the preceding year, we compared the efficacy and safety of two single-inhaler, triple fixed-dose combinations (i.e., budesonide at two different doses plus a LAMA and a LABA) with those of two dual therapies (LAMA–LABA and inhaled glucocorticoid–LABA).</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">The Efficacy and Safety of Triple Therapy in Obstructive Lung Disease (ETHOS) trial was a phase 3, randomized, double-blind, parallel-group trial conducted in 26 countries. The trial design has been published previously,<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-1" href-manipulated="true" aria-label="Reference 11">11</a></sup> and the trial <a href="#ap1">protocol</a> and statistical analysis plan are available with the full text of this article at NEJM.org. The protocol and informed consent form were approved by the appropriate institutional review board, independent ethics committee, or health authority; written informed consent was obtained from all patients before screening. An independent data monitoring committee and an independent clinical end-point committee reviewed safety data throughout the trial, including cardiovascular and cerebrovascular events, pneumonia, and cause-specific deaths.</div><div role="paragraph">The trial was designed by the sponsor (AstraZeneca) and the principal academic investigators. Data were collected by the clinical investigators and were analyzed by the employees of Everest Clinical Research Services and AstraZeneca. The first draft of the manuscript was written by a medical writer (funded by the sponsor) under the direction of the authors, in accordance with Good Publication Practice guidelines.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12" href-manipulated="true" aria-label="Reference 12">12</a></sup> All the authors critically reviewed and provided feedback on all subsequent versions of the manuscript and, along with the sponsor, made the decision to submit the manuscript for publication. All the authors had access to the data, contributed to the interpretation of the data, and vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol.</div></section><section id="sec-1-2"><h3>Patients and Randomization</h3><div role="paragraph">Eligible patients were 40 to 80 years of age and had symptomatic COPD (defined as a score of ≥10 on the COPD Assessment Test, on which scores range from 0 to 40, with higher scores indicating more symptoms; the minimum clinically important difference is 2 points); were receiving at least two inhaled maintenance therapies at the time of screening; had a postbronchodilator ratio of the forced expiratory volume in 1 second (FEV<sub>1</sub>) to the forced vital capacity of less than 0.7, with a postbronchodilator FEV<sub>1</sub> of 25 to 65% of the predicted normal value; had a smoking history of at least 10 pack-years; and had a documented history of at least one moderate or severe COPD exacerbation (if their FEV<sub>1</sub> was &lt;50% of the predicted normal value) or at least two moderate or at least one severe COPD exacerbation (if their FEV<sub>1</sub> was ≥50% of the predicted normal value) in the year before screening. Patients who had a current diagnosis of asthma were excluded, but those who had had asthma in the past (e.g., as a child or adolescent) were eligible. Investigators were advised not to enroll patients who had received a diagnosis of active asthma within the past 5 to 10 years.</div><div role="paragraph">Eligible patients were randomly assigned in a 1:1:1:1 ratio to receive triple therapy (an inhaled glucocorticoid at one of two dose levels [budesonide, 160 μg or 80 μg per inhaler actuation], a LAMA [glycopyrrolate, 9 μg per actuation], and a LABA [formoterol fumarate, 4.8 μg per actuation]) or one of two dual therapies (LAMA–LABA [glycopyrrolate, 9 μg per actuation, and formoterol fumarate, 4.8 μg per actuation] or inhaled glucocorticoid–LABA [budesonide, 160 μg per actuation, and formoterol fumarate, 4.8 μg per actuation]). All treatments were administered through identical metered-dose inhalers (Aerosphere, AstraZeneca) that were supplied by the sponsor. The patients received two doses per day over a 52-week period, and each dose consisted of two actuations (i.e., each dose of triple therapy delivered 320 μg or 160 μg of budesonide). Randomization was stratified according to exacerbation history (1 or ≥2 moderate or severe exacerbations), postbronchodilator FEV<sub>1</sub> (25 to &lt;50% or 50 to &lt;65% of the predicted normal value), blood eosinophil count (&lt;150 or ≥150 cells per cubic millimeter), and country. Patients discontinued maintenance medications for COPD after the first screening visit (except for inhaled glucocorticoids if used before screening) and received scheduled treatment with ipratropium and as-needed treatment with albuterol during the screening period (1 to 4 weeks). Ipratropium and inhaled glucocorticoids were discontinued at the time of randomization.</div></section><section id="sec-1-3"><h3>End Points</h3><div role="paragraph">The primary efficacy end point was the annual rate (the estimated mean number per patient per year) of moderate or severe COPD exacerbations. Moderate exacerbations were defined as those leading to treatment with systemic glucocorticoids, antibiotics, or both for at least 3 days; severe exacerbations were defined as those resulting in hospitalization or death. Secondary end points were defined according to the regional statistical approach used.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-2" href-manipulated="true" aria-label="Reference 11">11</a></sup> The secondary end points included in the statistical approach used in the United States were the time to the first moderate or severe COPD exacerbation, the change from baseline in average daily use of rescue medication over 24 weeks, the percentage of patients who had a St. George’s Respiratory Questionnaire (SGRQ) response (defined as a decrease from baseline in the total score on the SGRQ of ≥4 points at week 24 [total scores range from 0 to 100, with lower scores indicating better health-related quality of life; the minimum clinically important difference is 4 points]), the annual rate of severe COPD exacerbations, and time to death from any cause. Details of the secondary end points included in the statistical approach used outside the United States and of additional predefined end points are provided in Table S1 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div><div role="paragraph">Subgroup analyses of the primary end point were also performed. Three subgroup analyses were prespecified for subgroups defined according to exacerbation history (≥2 moderate or severe exacerbations in the preceding year), inhaled glucocorticoid use at the time of screening (using or not using inhaled glucocorticoids), and blood eosinophil count (&lt;150 or ≥150 cells per cubic millimeter); the subgroup analysis according to blood eosinophil count was supplemented by a generalized additive model predicting exacerbation rates on the basis of eosinophil count as a continuous variable. One subgroup analysis was performed post hoc for a subgroup defined according to bronchodilator reversibility at the time of screening (with or without bronchodilator reversibility, defined as an increase in FEV<sub>1</sub> of ≥12% and ≥200 ml after administration of albuterol).</div><div role="paragraph">A comprehensive framework, as described in recent regulatory guidelines,<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13" href-manipulated="true" aria-label="Reference 13">13</a></sup> was used to provide clarity in the description of estimates of treatment effect, including the handling of potentially confounding events, such as treatment discontinuations. Each approach is denoted by a different “estimand” — a target of estimation that includes the analysis population and the end-point variable or variables and prespecifies the way in which these confounding events will be handled in the analysis. Although this terminology is relatively new, analyses that use an efficacy estimand are similar to those traditionally used in previous trials evaluating COPD exacerbations, as is the approach of using a treatment policy estimand to evaluate time to death. Most efficacy analyses were conducted in the modified intention-to-treat population (all patients who underwent randomization, received a trial treatment, and had postrandomization data obtained before discontinuation of treatment) with the use of an efficacy estimand, which included only data obtained from patients while they were receiving a trial treatment. There were two exceptions: the secondary analysis of the primary end point and the analysis of time to death. The secondary analysis of the primary end point was conducted in the modified intention-to-treat population with the use of an attributable estimand, in which data obtained after treatment discontinuation due to lack of efficacy or adverse events were imputed as “poor responses.”<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14" href-manipulated="true" aria-label="Reference 14">14</a></sup> Time to death was assessed in the intention-to-treat population (all patients who underwent randomization and received any amount of trial treatment) with the use of a treatment policy estimand, which included all observed data obtained from patients regardless of whether they continued to receive their assigned treatment.</div><div role="paragraph">With respect to the primary end point, the treatment groups were compared in the following order: the 320-μg–budesonide triple-therapy group versus the glycopyrrolate–formoterol group, the 320-μg–budesonide triple-therapy group versus the budesonide–formoterol group, the 160-μg–budesonide triple-therapy group versus the glycopyrrolate–formoterol group (all to assess superiority), and the 160-μg–budesonide triple-therapy group versus the budesonide–formoterol group (to assess noninferiority and then superiority).</div><div role="paragraph">The safety population was similar to the modified intention-to-treat population, except that the patients were evaluated according to the treatment they received rather than to their assigned treatment; those with no postrandomization safety assessment were excluded. Safety assessments included physical examinations, vital signs, electrocardiograms, clinical laboratory tests, and monitoring of adverse events. Subgroups of patients also participated in substudies that included 4-hour pulmonary-function testing and 24-hour Holter monitoring, but the results are not reported in this article.</div></section><section id="sec-1-4"><h3>Statistical Analysis</h3><div role="paragraph">A sample size of 8400 patients was estimated to provide the trial with 93% power to detect a 15% lower annual rate of moderate or severe exacerbations in the 320-μg–budesonide triple-therapy group than in both the glycopyrrolate–formoterol group and the budesonide–formoterol group (96% power for each comparison), with type I error controlled at an equivalent of a two-sided alpha level of 0.05 (further details are provided in the <a href="#ap2">Supplementary Appendix</a>).</div><div role="paragraph">Rates of exacerbations were analyzed by means of negative binomial regression. Time-to-first-event analyses were performed with the use of Cox regression. The use of rescue medication was analyzed by means of a linear mixed model with repeated measures, and analysis of SGRQ response was performed with the use of logistic regression. For the comparison between the 160-μg–budesonide triple-therapy group and the budesonide–formoterol group, the noninferiority margin for exacerbation end points was a rate ratio of 1.1 for the upper bound of the two-sided 95% confidence interval.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patient Population</h3><div role="paragraph">A total of 8588 patients underwent randomization, and 8573 received a trial treatment (<a href="#f1">Figure 1</a>). The safety population comprised 8529 patients, and the intention-to-treat and modified intention-to-treat populations comprised 8509 patients each. A total of 7187 patients (83.8%) completed the trial, of whom 6654 (77.6%) completed 52 weeks of treatment (79.4% and 80.4% in the 320-μg–budesonide and 160-μg–budesonide triple-therapy groups, respectively, 74.1% in the glycopyrrolate–formoterol group, and 76.6% in the budesonide–formoterol group).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1916046_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1916046_f1.jpg"><img src="/cms/10.1056/NEJMoa1916046/asset/7146d115-33d7-4ddc-b19a-30372b6c95cb/assets/images/large/nejmoa1916046_f1.jpg" height="1816" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, and Treatment.</div><div class="notes"><div role="doc-footnote">Shown is the distribution of patients during screening, randomization, and treatment. The patients in the 320-μg–budesonide triple-therapy group received twice-daily doses of 320 μg of budesonide, 18 μg of glycopyrrolate, and 9.6 μg of formoterol fumarate; those in the 160-μg–budesonide triple-therapy group received twice-daily doses of 160 μg of budesonide, 18 μg of glycopyrrolate, and 9.6 μg of formoterol fumarate; those in the glycopyrrolate–formoterol group received twice-daily doses of 18 μg of glycopyrrolate and 9.6 μg of formoterol fumarate; and those in the budesonide–formoterol group received twice-daily doses of 320 μg of budesonide and 9.6 μg of formoterol fumarate. The intention-to-treat population included all patients who underwent randomization and received any amount of trial treatment. The modified intention-to-treat population included all patients in the intention-to-treat population with postrandomization data obtained before discontinuation of treatment. Any data collected after completion of, or discontinuation of, the assigned trial regimen was excluded from the modified intention-to-treat analysis but included in the intention-to-treat analysis. The safety population included all patients who underwent randomization, received any amount of treatment, and had a postrandomization safety assessment. Forty-four patients were excluded from all analysis populations because of overlapping treatment exposure from participating multiple times in the same study or participating concurrently in another study. An additional 20 patients were not included in the modified intention-to-treat population (8509 patients) because they had multiple enrollments, although with nonoverlapping treatment exposure (19 patients) or because of administrative reasons (1 patient); these patients were included in the safety population (8529 patients).</div></div></figcaption></figure></div><div role="paragraph">The demographic characteristics of the patients in the modified intention-to-treat population were similar across treatment groups (<a href="#t1">Table 1</a>). Overall, 80.5% of the patients were using inhaled glucocorticoids at the time of screening; other previously used COPD medications are listed in Table S3.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1916046_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1916046_t1.jpg"><img src="/cms/10.1056/NEJMoa1916046/asset/480ba503-31fd-4aa4-9267-057bd102629f/assets/images/large/nejmoa1916046_t1.jpg" height="2179" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">320-μg–Budesonide Triple Therapy <br>(N=2137)</th><th class="txxx-borders">160-μg–Budesonide Triple Therapy <br>(N=2121)</th><th class="txxx-borders">Glycopyrrolate–Formoterol<br>(N=2120)</th><th class="txxr-borders">Budesonide–Formoterol<br>(N=2131)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">64.6±7.6</td><td class="xxxx-borders shading">64.6±7.6</td><td class="xxxx-borders shading">64.8±7.6</td><td class="xxxr-borders shading">64.6±7.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders">1260 (59.0)</td><td class="xxxx-borders">1298 (61.2)</td><td class="xxxx-borders">1244 (58.7)</td><td class="xxxr-borders">1279 (60.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Current smoker — no. (%)</td><td class="xxxx-borders shading">910 (42.6)</td><td class="xxxx-borders shading">865 (40.8)</td><td class="xxxx-borders shading">856 (40.4)</td><td class="xxxr-borders shading">864 (40.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Pack-years of smoking</td><td class="xxxx-borders">47.0±25.1</td><td class="xxxx-borders">47.9±25.8</td><td class="xxxx-borders">48.4±26.5</td><td class="xxxr-borders">47.1±26.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">COPD exacerbations in the past 12 mo — no.</td><td class="xxxx-borders shading">1.7±0.8</td><td class="xxxx-borders shading">1.7±0.9</td><td class="xxxx-borders shading">1.7±0.8</td><td class="xxxr-borders shading">1.7±0.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">0 Moderate or severe — no. (%)</td><td class="xxxx-borders">2 (0.1)</td><td class="xxxx-borders">2 (0.1)</td><td class="xxxx-borders">2 (0.1)</td><td class="xxxr-borders">2 (0.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1 Moderate or severe — no. (%)</td><td class="xxxx-borders shading">940 (44.0)</td><td class="xxxx-borders shading">932 (43.9)</td><td class="xxxx-borders shading">907 (42.8)</td><td class="xxxr-borders shading">912 (42.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≥2 Moderate or severe — no. (%)</td><td class="xxxx-borders">1195 (55.9)</td><td class="xxxx-borders">1187 (56.0)</td><td class="xxxx-borders">1211 (57.1)</td><td class="xxxr-borders">1217 (57.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥1 Severe — no. (%)</td><td class="xxxx-borders shading">451 (21.1)</td><td class="xxxx-borders shading">463 (21.8)</td><td class="xxxx-borders shading">429 (20.2)</td><td class="xxxr-borders shading">458 (21.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Blood eosinophil count</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median (range) — cells/mm<sup>3</sup></td><td class="xxxx-borders shading">165 (0–2510)</td><td class="xxxx-borders shading">167 (5–1590)</td><td class="xxxx-borders shading">170 (5–2305)</td><td class="xxxr-borders shading">167 (0–2430)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≥150 cells/mm<sup>3</sup> — no. (%)</td><td class="xxxx-borders">1277 (59.8)</td><td class="xxxx-borders">1258 (59.3)</td><td class="xxxx-borders">1272 (60.0)</td><td class="xxxr-borders">1294 (60.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥300 cells/mm<sup>3</sup> — no. (%)</td><td class="xxxx-borders shading">310 (14.5)</td><td class="xxxx-borders shading">318 (15.0)</td><td class="xxxx-borders shading">293 (13.8)</td><td class="xxxr-borders shading">333 (15.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">FEV<sub>1</sub> after administration of albuterol — % of the predicted normal value</td><td class="xxxx-borders">43.6±10.3</td><td class="xxxx-borders">43.1±10.4</td><td class="xxxx-borders">43.5±10.2</td><td class="xxxr-borders">43.4±10.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">50 to &lt;80% of the predicted normal value: moderate COPD — no. (%)</td><td class="xxxx-borders shading">613 (28.7)</td><td class="xxxx-borders shading">604 (28.5)</td><td class="xxxx-borders shading">596 (28.1)</td><td class="xxxr-borders shading">614 (28.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">30 to &lt;50% of the predicted normal value: severe COPD — no. (%)</td><td class="xxxx-borders">1305 (61.1)</td><td class="xxxx-borders">1270 (59.9)</td><td class="xxxx-borders">1293 (61.0)</td><td class="xxxr-borders">1283 (60.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">&lt;30% of the predicted normal value: very severe COPD — no. (%)</td><td class="xxxx-borders shading">217 (10.2)</td><td class="xxxx-borders shading">245 (11.6)</td><td class="xxxx-borders shading">229 (10.8)</td><td class="xxxr-borders shading">233 (10.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Change in FEV<sub>1</sub> from before to after administration of albuterol — ml</td><td class="xxxx-borders">146.3±158.0</td><td class="xxxx-borders">144.4±151.7</td><td class="xxxx-borders">148.7±151.1</td><td class="xxxr-borders">142.3±144.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Bronchodilator reversibility — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">657 (30.7)</td><td class="xxxx-borders shading">631 (29.8)</td><td class="xxxx-borders shading">669 (31.6)</td><td class="xxxr-borders shading">654 (30.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Use of inhaled glucocorticoid at screening — no. (%)</td><td class="xxxx-borders">1706 (79.8)</td><td class="xxxx-borders">1729 (81.5)</td><td class="xxxx-borders">1707 (80.5)</td><td class="xxxr-borders">1704 (80.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">COPD Assessment Test score<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xbxx-borders shading">19.7±6.5</td><td class="xbxx-borders shading">19.6±6.6</td><td class="xbxx-borders shading">19.5±6.6</td><td class="xbxr-borders shading">19.5±6.5</td></tr></tbody></table></div><figcaption><div class="caption">Demographic Characteristics of the Patients at Baseline (Modified Intention-to-Treat Population).<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. The modified intention-to-treat population included all patients who underwent randomization, received any amount of trial treatment, and had postrandomization data obtained before discontinuation of treatment. The 320-μg–budesonide triple-therapy group received twice daily doses of 320 μg of budesonide, 18 μg of glycopyrrolate, and 9.6 μg of formoterol fumarate; the 160-μg–budesonide triple-therapy group received twice-daily doses of 160 μg of budesonide, 18 μg of glycopyrrolate, and 9.6 μg of formoterol fumarate; the glycopyrrolate–formoterol group received twice-daily doses of 18 μg of glycopyrrolate and 9.6 μg of formoterol fumarate; and the budesonide–formoterol group received twice-daily doses of 320 μg of budesonide and 9.6 μg of formoterol fumarate. The doses of glycopyrrolate and formoterol fumarate are equivalent to 14.4 μg of glycopyrronium and 10 μg of formoterol fumarate dihydrate, respectively. COPD denotes chronic obstructive pulmonary disease, and FEV<sub>1</sub> forced expiratory volume in 1 second.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Bronchodilator reversibility was defined as an increase in FEV<sub>1</sub> of at least 12% and at least 200 ml after administration of albuterol.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Scores on the COPD Assessment Test range from 0 to 40, with higher scores indicating more symptoms; the minimum clinically important difference in score is 2 points.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Primary Efficacy Analyses</h3><div role="paragraph">The model-estimated annual rates of moderate or severe exacerbations were 1.08 in the 320-μg–budesonide triple-therapy group, 1.07 in the 160-μg–budesonide triple-therapy group, 1.42 in the glycopyrrolate–formoterol group, and 1.24 in the budesonide–formoterol group. The annual rate of moderate or severe exacerbations was significantly lower with 320-μg–budesonide triple therapy than with glycopyrrolate–formoterol (24% lower: rate ratio, 0.76; 95% confidence interval [CI], 0.69 to 0.83; P&lt;0.001) or budesonide–formoterol (13% lower: rate ratio, 0.87; 95% CI, 0.79 to 0.95; P=0.003). Similarly, the annual rate of moderate or severe exacerbation was significantly lower with 160-μg–budesonide triple therapy than with glycopyrrolate–formoterol (25% lower: rate ratio, 0.75; 95% CI, 0.69 to 0.83; P&lt;0.001) or budesonide–formoterol (14% lower: rate ratio, 0.86; 95% CI, 0.79 to 0.95; P=0.002) (<a href="#t2">Table 2</a>). No difference was observed between the two triple-therapy groups (rate ratio, 1.00; 95% CI, 0.91 to 1.10).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1916046_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1916046_t2.jpg"><img src="/cms/10.1056/NEJMoa1916046/asset/60daa192-9199-492c-9bf2-9699047bd093/assets/images/large/nejmoa1916046_t2.jpg" height="3194" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="xxxx-borders" data-xml-align="left">End Point</th><th class="xxxx-borders">320-μg–Budesonide<br>Triple Therapy<br>(N=2137)</th><th class="xxxx-borders">160-μg–Budesonide<br>Triple Therapy<br>(N=2121)</th><th class="xxxx-borders">Glycopyrrolate–<br>Formoterol<br>(N=2120)</th><th class="xxxx-borders">Budesonide–<br>Formoterol<br>(N=2131)</th></tr></thead><tbody><tr data-type="row"><td class="xxxx-borders hanging03 shading"><b>Primary end point</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03" data-xml-align="left">Primary analysis: model-estimated annual rate of moderate or severe COPD exacerbations</td><td class="xxxx-borders">1.08</td><td class="xxxx-borders">1.07</td><td class="xxxx-borders">1.42</td><td class="xxxx-borders">1.24</td></tr><tr data-type="row"><td class="xxxx-borders hanging13 shading">320-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">Rate ratio for moderate or severe exacerbations (95% CI)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">1.00 (0.91–1.10)</td><td class="xxxx-borders">0.76 (0.69–0.83)</td><td class="xxxx-borders">0.87 (0.79–0.95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">P value<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">0.003</td></tr><tr data-type="row"><td class="xxxx-borders hanging13">160-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">Rate ratio for moderate or severe exacerbations (95% CI)</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">0.75 (0.69–0.83)</td><td class="xxxx-borders shading">0.86 (0.79–0.95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">P value</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">0.002</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03 shading" data-xml-align="left">Secondary analysis: model-estimated annual rate of moderate or severe COPD exacerbations (attributable estimand)<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">1.25</td><td class="xxxx-borders shading">1.23</td><td class="xxxx-borders shading">1.63</td><td class="xxxx-borders shading">1.47</td></tr><tr data-type="row"><td class="xxxx-borders hanging13">320-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">Rate ratio for moderate or severe exacerbations (95% CI)</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">1.01 (0.94–1.10)</td><td class="xxxx-borders shading">0.76 (0.71–0.83)</td><td class="xxxx-borders shading">0.85 (0.78–0.92)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">P value<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">—</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&lt;0.001</td></tr><tr data-type="row"><td class="xxxx-borders hanging13 shading">160-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">Rate ratio for moderate or severe exacerbations (95% CI)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">0.75 (0.70–0.82)</td><td class="xxxx-borders">0.84 (0.77–0.90)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">P value</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&lt;0.001</td></tr><tr data-type="row"><td class="xxxx-borders hanging03"><b>Secondary exacerbation and mortality end points</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">Time to first moderate or severe COPD exacerbation over 52 wk</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">Patients with exacerbations — no. (%)</td><td class="xxxx-borders">1026 (48.0)</td><td class="xxxx-borders">1013 (47.8)</td><td class="xxxx-borders">1056 (49.8)</td><td class="xxxx-borders">1085 (50.9)</td></tr><tr data-type="row"><td class="xxxx-borders hanging13 shading">320-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">Hazard ratio for moderate or severe exacerbation (95% CI)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">1.02 (0.93–1.11)</td><td class="xxxx-borders">0.88 (0.81–0.96)</td><td class="xxxx-borders">0.89 (0.81–0.97)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">P value<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">0.004</td><td class="xxxx-borders shading">0.006</td></tr><tr data-type="row"><td class="xxxx-borders hanging13">160-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">Hazard ratio for moderate or severe exacerbation (95% CI)</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">0.87 (0.79–0.94)</td><td class="xxxx-borders shading">0.87 (0.80–0.95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">P value</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.001</td><td class="xxxx-borders">0.002</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03 shading" data-xml-align="left">Model-estimated annual rate of severe COPD exacerbations</td><td class="xxxx-borders shading">0.13</td><td class="xxxx-borders shading">0.14</td><td class="xxxx-borders shading">0.15</td><td class="xxxx-borders shading">0.16</td></tr><tr data-type="row"><td class="xxxx-borders hanging13">320-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">Rate ratio for severe exacerbations (95% CI)</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">0.96 (0.78–1.17)</td><td class="xxxx-borders shading">0.84 (0.69–1.03)</td><td class="xxxx-borders shading">0.80 (0.66–0.97)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">P value<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">—</td><td class="xxxx-borders">0.09</td><td class="xxxx-borders">0.02</td></tr><tr data-type="row"><td class="xxxx-borders hanging13 shading">160-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">Rate ratio for severe exacerbations (95% CI)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">0.88 (0.72–1.08)</td><td class="xxxx-borders">0.83 (0.69–1.01)</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">Time to death from any cause over 52 wk (treatment policy estimand)<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">Patient deaths — no. (%)</td><td class="xxxx-borders">28 (1.3)</td><td class="xxxx-borders">39 (1.8)</td><td class="xxxx-borders">49 (2.3)</td><td class="xxxx-borders">34 (1.6)</td></tr><tr data-type="row"><td class="xxxx-borders hanging13 shading">320-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">Hazard ratio for death (95% CI)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">0.69 (0.42–1.13)</td><td class="xxxx-borders">0.54 (0.34–0.87)</td><td class="xxxx-borders">0.78 (0.47–1.30)</td></tr><tr data-type="row"><td class="xxxx-borders hanging13 shading">160-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">Hazard ratio for death (95% CI)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">0.79 (0.52–1.20)</td><td class="xxxx-borders">1.13 (0.72–1.80)</td></tr></tbody></table></div><figcaption><div class="caption">Efficacy End Points.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Efficacy analyses were performed in the modified intention-to-treat population with the use of an efficacy estimand, unless otherwise specified; the efficacy estimand included only data obtained from patients while they were receiving a trial treatment. The annual rate is the estimated mean number of exacerbations per patient per year. Additional secondary end points are reported in Table S4.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Comparisons between the 320-μg–budesonide triple-therapy group and the 160-μg–budesonide triple-therapy group were not included in the testing hierarchy and thus no P values are provided.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">The secondary analysis of the primary end point was performed with an attributable estimand, where data obtained after treatment discontinuation due to lack of efficacy or adverse events were imputed as “poor responses.”</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">The analysis of time to death from any cause over 52 weeks was performed in the intention-to-treat population (all patients who underwent randomization and received any amount of trial treatment) with the use of a treatment policy estimand, which included all observed data from the patients regardless of whether they continued to receive their assigned treatment.</div></div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Secondary and Other Efficacy Analyses</h3><div role="paragraph">In the secondary analysis of the primary end point, the rate ratios of moderate or severe exacerbations that were determined with the use of the attributable estimand were similar to the rate ratios in the primary analysis (<a href="#t2">Table 2</a>). Both triple-therapy regimens significantly prolonged the time to the first moderate or severe exacerbation as compared with both dual therapies (<a href="#f2">Figure 2A</a> and <a href="#t2">Table 2</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1916046_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1916046_f2.jpg"><img src="/cms/10.1056/NEJMoa1916046/asset/e929749f-b349-4e07-80fc-26f5fac1d565/assets/images/large/nejmoa1916046_f2.jpg" height="3438" width="2303" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Estimates of the Cumulative Incidence of Moderate or Severe COPD Exacerbations and Death from Any Cause in Time-to-First-Event Analyses.</div><div class="notes"><div role="doc-footnote">Panel A shows the time to the first moderate or severe exacerbation of chronic obstructive pulmonary disease (COPD). The analysis was performed in the modified intention-to-treat population with the use of an efficacy estimand, which included only data obtained from patients while they were receiving a trial treatment. Panel B shows the time to death from any cause. The analysis was performed in the intention-to-treat population with the use of a treatment policy estimand, which included all observed data obtained from the patients regardless of whether they continued to receive their assigned treatment. The inset shows the same data on an enlarged y axis. Tick marks indicate the time of data censoring.</div></div></figcaption></figure></div><div role="paragraph">The model-estimated annual rates of severe exacerbations were 0.13 in the 320-μg–budesonide triple-therapy group, 0.14 in the 160-μg–budesonide triple-therapy group, 0.15 in the glycopyrrolate–formoterol group, and 0.16 in the budesonide–formoterol group. The rate ratio of severe exacerbations over 52 weeks in the 320-μg–budesonide triple-therapy group was 16% lower than in the glycopyrrolate–formoterol group (0.84; 95% CI, 0.69 to 1.03; P=0.09) and 20% lower than in the budesonide–formoterol group (0.80; 95% CI, 0.66 to 0.97; P=0.02). In the noninferiority analysis of the annual rate of severe exacerbations that was performed in the per-protocol population (all patients with postrandomization data obtained before any major protocol deviations), 160-μg–budesonide triple therapy was shown to be noninferior to budesonide–formoterol (rate ratio, 0.82; 95% CI, 0.68 to 1.00); however, differences between the 160-μg–budesonide triple-therapy group and either dual-therapy group were not significant (<a href="#t2">Table 2</a>). The change from baseline in the use of rescue medication over 24 weeks and the proportion of patients with an SGRQ response at week 24 are shown in Table S4.</div><div role="paragraph">In time-to-first-event analyses performed with the use of the treatment policy estimand in the intention-to-treat population, the risk of death from any cause in the 320-μg–budesonide triple-therapy group was 46% lower than that in the glycopyrrolate–formoterol group (28 vs. 49 deaths; hazard ratio, 0.54; 95% CI, 0.34 to 0.87) and 22% lower than that in the budesonide–formoterol group (28 vs. 34 deaths; hazard ratio, 0.78; 95% CI, 0.47 to 1.30). The risk of death from any cause in the 160-μg–budesonide triple-therapy group was lower than that in the glycopyrrolate–formoterol group (39 vs. 49 deaths; hazard ratio, 0.79; 95% CI, 0.52 to 1.20) but higher than that in the budesonide–formoterol group (39 vs. 34 deaths; hazard ratio, 1.13; 95% CI, 0.72 to 1.80) (<a href="#f2">Figure 2B</a> and <a href="#t2">Table 2</a>). Adjudicated causes of death are provided in Table S5.</div><div role="paragraph">Data on prespecified subgroup analyses of the rates of moderate or severe exacerbations according to baseline eosinophil counts, the use of inhaled glucocorticoids at the time of screening, and bronchodilator reversibility at the time of screening are provided in Figures S4 and S5 and Table S6. The triple-therapy regimens showed a benefit over the dual-therapy regimens with respect to the annual rate of moderate or severe exacerbations in both eosinophil subgroups (&lt;150 and ≥150 cells per cubic millimeter) and regardless of whether the patients were using inhaled glucocorticoids or had bronchodilator reversibility at the time of screening.</div></section><section id="sec-2-4"><h3>Safety and Adverse-Event Profile</h3><div role="paragraph">The percentage of patients who had at least one adverse event ranged from 61.7 to 64.5% across treatment groups. The percentage of patients who had serious adverse events ranged from 19.9 to 21.0% across treatment groups. The most frequently reported adverse events overall were nasopharyngitis (10.5%), COPD (10.4%), and upper respiratory tract infection (5.6%) (<a href="#t3">Table 3</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1916046_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1916046_t3.jpg"><img src="/cms/10.1056/NEJMoa1916046/asset/b3867119-d5c8-4533-ac0e-1e537cc6d716/assets/images/large/nejmoa1916046_t3.jpg" height="1435" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="2"><span>320-μg–Budesonide Triple Therapy<br>(N=2144)</span></th><th class="txxx-borders" colspan="2"><span>160-μg–Budesonide Triple Therapy<br>(N=2124)</span></th><th class="txxx-borders" colspan="2"><span>Glycopyrrolate–Formoterol<br>(N=2125)</span></th><th class="txxr-borders" colspan="2"><span>Budesonide–Formoterol<br>(N=2136)</span></th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">no. of patients (%)</th><th class="xxxx-borders">no. of events<br>(no. per 1000 patient-yr)</th><th class="xxxx-borders">no. of patients (%)</th><th class="xxxx-borders">no. of events<br>(no. per 1000 patient-yr)</th><th class="xxxx-borders">no. of patients (%)</th><th class="xxxx-borders">no. of events<br>(no. per 1000 patient-yr)</th><th class="xxxx-borders">no. of patients (%)</th><th class="xxxr-borders">no. of events<br>(no. per 1000 patient-yr)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">1368 (63.8)</td><td class="xxxx-borders shading">4527 (2388.4)</td><td class="xxxx-borders shading">1356 (63.8)</td><td class="xxxx-borders shading">4382 (2318.7)</td><td class="xxxx-borders shading">1312 (61.7)</td><td class="xxxx-borders shading">4074 (2301.7)</td><td class="xxxx-borders shading">1377 (64.5)</td><td class="xxxr-borders shading">4746 (2587.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serious adverse events</td><td class="xxxx-borders">426 (19.9)</td><td class="xxxx-borders">664 (350.3)</td><td class="xxxx-borders">445 (21.0)</td><td class="xxxx-borders">681 (360.3)</td><td class="xxxx-borders">433 (20.4)</td><td class="xxxx-borders">639 (361.0)</td><td class="xxxx-borders">440 (20.6)</td><td class="xxxr-borders">653 (355.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse events that led to early discontinuation</td><td class="xxxx-borders shading">119 (5.6)</td><td class="xxxx-borders shading">150 (79.1)</td><td class="xxxx-borders shading">112 (5.3)</td><td class="xxxx-borders shading">146 (77.3)</td><td class="xxxx-borders shading">146 (6.9)</td><td class="xxxx-borders shading">187 (105.7)</td><td class="xxxx-borders shading">140 (6.6)</td><td class="xxxr-borders shading">160 (87.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Confirmed major adverse cardiovascular event<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">31 (1.4)</td><td class="xxxx-borders">32 (16.9)</td><td class="xxxx-borders">30 (1.4)</td><td class="xxxx-borders">31 (16.4)</td><td class="xxxx-borders">44 (2.1)</td><td class="xxxx-borders">47 (26.6)</td><td class="xxxx-borders">23 (1.1)</td><td class="xxxr-borders">24 (13.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Confirmed pneumonia<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">90 (4.2)</td><td class="xxxx-borders shading">93 (49.1)</td><td class="xxxx-borders shading">75 (3.5)</td><td class="xxxx-borders shading">78 (41.3)</td><td class="xxxx-borders shading">48 (2.3)</td><td class="xxxx-borders shading">51 (28.8)</td><td class="xxxx-borders shading">96 (4.5)</td><td class="xxxr-borders shading">106 (57.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Deaths from any cause during treatment period</td><td class="xxxx-borders">20 (0.9)</td><td class="xxxx-borders">19 (10.0)<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">28 (1.3)</td><td class="xxxx-borders">28 (14.8)</td><td class="xxxx-borders">35 (1.6)</td><td class="xxxx-borders">35 (19.8)</td><td class="xxxx-borders">29 (1.4)</td><td class="xxxr-borders">29 (15.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Adverse events that occurred in ≥3% of patients overall</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders">227 (10.6)</td><td class="xxxx-borders">290 (153.0)</td><td class="xxxx-borders">239 (11.3)</td><td class="xxxx-borders">315 (166.7)</td><td class="xxxx-borders">199 (9.4)</td><td class="xxxx-borders">255 (144.1)</td><td class="xxxx-borders">234 (11.0)</td><td class="xxxr-borders">331 (180.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">COPD</td><td class="xxxx-borders shading">203 (9.5)</td><td class="xxxx-borders shading">256 (135.1)</td><td class="xxxx-borders shading">221 (10.4)</td><td class="xxxx-borders shading">263 (139.2)</td><td class="xxxx-borders shading">219 (10.3)</td><td class="xxxx-borders shading">268 (151.4)</td><td class="xxxx-borders shading">242 (11.3)</td><td class="xxxr-borders shading">300 (163.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders">123 (5.7)</td><td class="xxxx-borders">149 (78.6)</td><td class="xxxx-borders">137 (6.5)</td><td class="xxxx-borders">176 (93.1)</td><td class="xxxx-borders">102 (4.8)</td><td class="xxxx-borders">129 (72.9)</td><td class="xxxx-borders">115 (5.4)</td><td class="xxxr-borders">154 (83.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pneumonia</td><td class="xxxx-borders shading">98 (4.6)</td><td class="xxxx-borders shading">101 (53.3)</td><td class="xxxx-borders shading">85 (4.0)</td><td class="xxxx-borders shading">93 (49.2)</td><td class="xxxx-borders shading">61 (2.9)</td><td class="xxxx-borders shading">66 (37.3)</td><td class="xxxx-borders shading">107 (5.0)</td><td class="xxxr-borders shading">117 (63.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Bronchitis</td><td class="xbxx-borders">66 (3.1)</td><td class="xbxx-borders">74 (39.0)</td><td class="xbxx-borders">68 (3.2)</td><td class="xbxx-borders">76 (40.2)</td><td class="xbxx-borders">76 (3.6)</td><td class="xbxx-borders">81 (45.8)</td><td class="xbxx-borders">69 (3.2)</td><td class="xbxr-borders">83 (45.2)</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events during the 52-Week Treatment Period (Safety Population).<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">The safety population included all patients who underwent randomization, received treatment, and had any postrandomization safety assessment.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">Confirmation was obtained from an independent clinical end-point committee.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">A total of 20 patients in the 320-μg–budesonide triple-therapy group had adverse events while they were receiving treatment that were linked to an outcome of death; however, death in 1 patient was adjudicated on the basis of a post-treatment adverse event and therefore was not included in the calculation of the event rate in the on-treatment analysis.</div></div></div></figcaption></figure></div><div role="paragraph">The incidence of confirmed pneumonia ranged from 3.5 to 4.5% in the treatment groups that received an inhaled glucocorticoid (41.3 to 57.8 events per 1000 patient-years) and was 2.3% in the glycopyrrolate–formoterol group (28.8 events per 1000 patient-years). The time to the first confirmed pneumonia event was longer in the glycopyrrolate–formoterol group than in the treatment groups that received an inhaled glucocorticoid (P&lt;0.05 for all comparisons) (Table S7). The incidence of serious confirmed pneumonia events was higher in the treatment groups that received an inhaled glucocorticoid (range, 2.4 to 3.0%) than in the glycopyrrolate–formoterol group (1.3%) (P&lt;0.05 for all comparisons) (<a href="#t3">Table 3</a> and Table S8). A similar pattern was observed for pharmacologically expected local effects of glucocorticoids (dysphonia and candidiasis), with a lower incidence in the glycopyrrolate–formoterol group than in the treatment groups that received an inhaled glucocorticoid (P&lt;0.05 for all comparisons), whereas the incidence of other systemic effects of glucocorticoids (diabetes mellitus, bone fracture, and ocular effects) were similar across treatment groups (P&gt;0.05 for all comparisons; Table S10). No clinically meaningful differences in vital signs, electrocardiogram findings, or clinical laboratory test results were observed among the treatment groups.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In this randomized trial involving more than 8500 patients with moderate-to-very-severe COPD, single-inhaler triple therapy with an inhaled glucocorticoid (budesonide, 320 μg or 160 μg twice daily) plus LAMA–LABA (glycopyrrolate–formoterol) resulted in significantly lower rates of moderate or severe exacerbations than dual therapy with LAMA–LABA or inhaled glucocorticoid–LABA. In addition, both triple-therapy regimens significantly improved patient-reported outcomes as compared with either dual-therapy regimen.</div><div role="paragraph">The ETHOS trial assessed two different doses of an inhaled glucocorticoid in fixed-dose triple therapy for COPD. Although a statistical evaluation of a dose–response relationship was not part of our testing hierarchy and the trial was not powered to detect a significant difference between the triple-therapy regimens, unadjusted comparisons between these regimens showed similar efficacy with respect to most exacerbation-related end points. These comparisons also showed trends in favor of 320-μg–budesonide triple therapy with respect to severe exacerbations, SGRQ response, and use of rescue medication. Furthermore, despite a mortality of 1.8% overall, when the triple-therapy regimens were compared with glycopyrrolate–formoterol, a lower risk of death from any cause was observed only in the 320-μg–budesonide triple-therapy group, as shown by the 95% confidence interval. The hazard ratio for death from any cause in the 320-μg–budesonide triple-therapy group, as compared with the 160-μg–budesonide triple-therapy group, was 0.69, but the 95% confidence interval was 0.42 to 1.13, which precluded any definitive conclusions regarding a dose–response relationship. This is the second trial to show a benefit of triple therapy over dual therapy with LAMA–LABA with respect to mortality among patients with COPD. In analyses including both on-treatment and off-treatment data, the risk of death from any cause was 46% lower in the ETHOS trial (for 320-μg–budesonide triple therapy vs. glycopyrrolate-formoterol) and 29% lower in the Informing the Pathway of COPD Treatment (IMPACT) trial (for triple therapy with fluticasone furoate–umeclidinium–vilanterol vs. umeclidinium–vilanterol).<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-2" href-manipulated="true" aria-label="Reference 4">4</a></sup> The difference observed between the 320-μg–budesonide and the 160-μg–budesonide triple-therapy groups with respect to mortality but not the other end points is unexplained but may reflect a beneficial effect on cardiovascular outcomes in this high-risk population. This possibility has been previously suggested by the findings from the Towards a Revolution in COPD Health (TORCH) trial,<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15 r16" id="body-ref-r16" href-manipulated="true">15,16</a></sup> but was not proven in a subsequent interventional study involving patients with cardiovascular risk factors but less severe respiratory disease (Study to Understand Mortality and Morbidity in COPD [SUMMIT]).<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17" href-manipulated="true" aria-label="Reference 17">17</a></sup></div><div role="paragraph">The lower rates of moderate or severe exacerbations in the triple-therapy groups than in the dual-therapy groups in the ETHOS trial were similar to the findings from previous 52-week trials, including the IMPACT, TRILOGY, and TRIBUTE trials.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r5 r6" id="body-ref-r6-2" href-manipulated="true">4-6</a></sup> In addition, the results of the ETHOS trial further build on the findings from the KRONOS trial, a 24-week trial that showed benefits of triple therapy with a 320-μg dose of budesonide plus glycopyrrolate and formoterol over dual therapies with respect to lung function, symptoms, and exacerbations for COPD in a population in which most patients (74%) had not had an exacerbation in the preceding year.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2-2" href-manipulated="true" aria-label="Reference 2">2</a></sup> It has been proposed that the benefits of triple therapy over LAMA–LABA therapy in previous studies may have resulted from a short-term increase in the rates of exacerbations in the LAMA–LABA groups due to the discontinuation of inhaled glucocorticoids in patients who had been using inhaled glucocorticoids before trial entry.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> However, in the ETHOS trial, the benefits of both triple-therapy regimens over the LAMA–LABA regimen were similar among the patients who were using inhaled glucocorticoids at the time of screening and those who were not; this finding indicates that the results were not driven by the immediate discontinuation of inhaled glucocorticoids.</div><div role="paragraph">Current recommendations from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) suggest that patients with elevated eosinophil levels who continue to have exacerbations while receiving a single bronchodilator regimen with either a LAMA or a LABA should initially step up to inhaled glucocorticoid–LABA therapy.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-3" href-manipulated="true" aria-label="Reference 1">1</a></sup> In the current trial, triple therapy with a 160-μg dose of budesonide showed significant benefits over inhaled glucocorticoid–LABA therapy with a 320-μg dose of budesonide with respect to exacerbations and symptoms, a finding that calls into question the role for inhaled glucocorticoid–LABA therapy in patients with moderate-to-very-severe COPD who are symptomatic and have a history of exacerbations. In the subgroups defined according to blood eosinophil counts, the benefits of triple therapy (with either dose of budesonide) over LAMA–LABA therapy with respect to exacerbations were greater among the patients with higher counts, a finding consistent with observations in previous studies of the response to inhaled glucocorticoids,<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19 r20" id="body-ref-r20" href-manipulated="true">19,20</a></sup> as well as with the current GOLD recommendations.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-4" href-manipulated="true" aria-label="Reference 1">1</a></sup></div><div role="paragraph">No unexpected safety signals were identified in the ETHOS trial. As previously shown in other 52-week trials involving patients with COPD,<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r21" id="body-ref-r21" href-manipulated="true">4,21</a></sup> the incidence of pneumonia was higher in the treatment groups that received an inhaled glucocorticoid than in those that received the LAMA–LABA combination. The incidence of confirmed pneumonia was higher in the 160-μg–budesonide triple-therapy group (3.5%), the 320-μg–budesonide triple-therapy group (4.2%), and the budesonide–formoterol group (4.5%) than in the glycopyrrolate–formoterol group (2.3%). Across treatment groups, the incidence of pneumonia was higher in the ETHOS trial than in the Key Assessment of Triple Therapy on Lung Function in Obstructive Lung Disease (KRONOS) trial (1.3 to 1.9%),<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2-3" href-manipulated="true" aria-label="Reference 2">2</a></sup> which may reflect the longer duration of the current trial as well as the differences in patient populations; the current trial involved patients with more severe airflow limitation and frequent exacerbations, which have been associated with a greater risk of pneumonia.<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22" href-manipulated="true" aria-label="Reference 22">22</a></sup></div><div role="paragraph">In conclusion, our findings show the benefits of triple therapy with a budesonide–glycopyrrolate–formoterol combination over dual therapy with a LAMA–LABA or an inhaled glucocorticoid–LABA combination with respect to the annual rate of moderate or severe COPD exacerbations, symptoms, and health-related quality of life in patients with moderate-to-very-severe COPD who are at risk of exacerbations. Triple therapy with a 320-μg dose of budesonide also resulted in a lower all-cause mortality than LAMA–LABA therapy. We also showed that triple therapy with a 160-μg dose of budesonide was an effective treatment option for COPD; this lower-dose inhaled glucocorticoid triple-therapy regimen showed greater efficacy than the higher-dose inhaled glucocorticoid–LABA regimen, with lower rates of exacerbations, greater reductions in symptoms, and greater improvement in health-related quality of life.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was published on June 24, 2020, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">AstraZeneca</span>. Dr. Singh is supported by the National Institute for Health Research, Manchester Biomedical Research Centre.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank all the patients, their families, and the team of investigators, research nurses, and operations staff involved in the ETHOS trial, and Julia King, Ph.D., of CMC Connect, McCann Health Medical Communications, for medical writing support.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa1916046_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1916046/suppl_file/nejmoa1916046_protocol.pdf" download="nejmoa1916046_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1916046_protocol.pdf" data-doi="10.1056/NEJMoa1916046">Download</a></li><li>12.66 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa1916046_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1916046/suppl_file/nejmoa1916046_appendix.pdf" download="nejmoa1916046_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1916046_appendix.pdf" data-doi="10.1056/NEJMoa1916046">Download</a></li><li>853.08 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa1916046_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1916046/suppl_file/nejmoa1916046_disclosures.pdf" download="nejmoa1916046_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1916046_disclosures.pdf" data-doi="10.1056/NEJMoa1916046">Download</a></li><li>312.00 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa1916046_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1916046/suppl_file/nejmoa1916046_data-sharing.pdf" download="nejmoa1916046_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1916046_data-sharing.pdf" data-doi="10.1056/NEJMoa1916046">Download</a></li><li>75.59 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Global Initiative for Chronic Obstructive Lung Disease. 2020 Report: global strategy for prevention, diagnosis and management of COPD (<a href="https://goldcopd.org/gold-reports/">https://goldcopd.org/gold-reports/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Global+Initiative+for+Chronic+Obstructive+Lung+Disease.+2020+Report%3A+global+strategy+for+prevention%2C+diagnosis+and+management+of+COPD+%28https%3A%2F%2Fgoldcopd.org%2Fgold-reports%2F%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r1-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and reduce or eliminate exacerbations, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] LAMA–LABA or inhaled glucocorticoid–LABA. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] up to inhaled glucocorticoid–LABA therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] as with the current GOLD recommendations. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. <em>Lancet Respir Med</em> 2018;6:747-758.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-2600(18)30327-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30232048/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000445806700019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Triple+therapy+with+budesonide%2Fglycopyrrolate%2Fformoterol+fumarate+with+co-suspension+delivery+technology+versus+dual+therapies+in+chronic+obstructive+pulmonary+disease+%28KRONOS%29%3A+a+double-blind%2C+parallel-group%2C+multicentre%2C+phase+3+randomised+controlled+trial.&amp;publication_year=2018&amp;journal=Lancet+Respir+Med&amp;pages=747-758&amp;doi=10.1016%2FS2213-2600%2818%2930327-8&amp;pmid=30232048" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] quality of life than dual therapies </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] had an exacerbation in the preceding year. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] Lung Disease (KRONOS) trial (1.3 to 1.9%), </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. <em>Am J Respir Crit Care Med</em> 2017;196:438-446.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.201703-0449OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28375647/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000407532700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=FULFIL+trial%3A+once-daily+triple+therapy+for+patients+with+chronic+obstructive+pulmonary+disease.&amp;publication_year=2017&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=438-446&amp;doi=10.1164%2Frccm.201703-0449OC&amp;pmid=28375647" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. <em>N Engl J Med</em> 2018;378:1671-1680.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_5_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1916046&amp;key=10.1056%2FNEJMoa1713901&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29668352/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000431218600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Once-daily+single-inhaler+triple+versus+dual+therapy+in+patients+with+COPD.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=1671-1680&amp;doi=10.1056%2FNEJMoa1713901&amp;pmid=29668352" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] quality of life than dual therapies </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] vs. umeclidinium–vilanterol). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] the IMPACT, TRILOGY, and TRIBUTE trials. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] trials involving patients with COPD, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. <em>Lancet</em> 2018;391:1076-1084.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)30206-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29429593/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000427585100026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Extrafine+inhaled+triple+therapy+versus+dual+bronchodilator+therapy+in+chronic+obstructive+pulmonary+disease+%28TRIBUTE%29%3A+a+double-blind%2C+parallel+group%2C+randomised+controlled+trial.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=1076-1084&amp;doi=10.1016%2FS0140-6736%2818%2930206-X&amp;pmid=29429593" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] quality of life than dual therapies </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the IMPACT, TRILOGY, and TRIBUTE trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β<sub>2</sub>-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. <em>Lancet</em> 2016;388:963-973.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)31354-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27598678/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000382524400026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Single+inhaler+triple+therapy+versus+inhaled+corticosteroid+plus+long-acting+%CE%B22-agonist+therapy+for+chronic+obstructive+pulmonary+disease+%28TRILOGY%29%3A+a+double-blind%2C+parallel+group%2C+randomised+controlled+trial.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=963-973&amp;doi=10.1016%2FS0140-6736%2816%2931354-X&amp;pmid=27598678" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] quality of life than dual therapies </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the IMPACT, TRILOGY, and TRIBUTE trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. <em>Cochrane Database Syst Rev</em> 2014;3:CD010115-CD010115.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24615270/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000333667600029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inhaled+steroids+and+risk+of+pneumonia+for+chronic+obstructive+pulmonary+disease.&amp;publication_year=2014&amp;journal=Cochrane+Database+Syst+Rev&amp;pages=CD010115-CD010115&amp;pmid=24615270" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. <em>N Engl J Med</em> 1997;337:8-14.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_9_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1916046&amp;key=10.1056%2FNEJM199707033370102&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9203425/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1997XH18600002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Use+of+inhaled+corticosteroids+and+the+risk+of+cataracts.&amp;publication_year=1997&amp;journal=N+Engl+J+Med&amp;pages=8-14&amp;doi=10.1056%2FNEJM199707033370102&amp;pmid=9203425" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. <em>Thorax</em> 2013;68:1029-1036.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/thoraxjnl-2012-202872" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24130228/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000326048900011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inhaled+corticosteroids+in+COPD+and+the+risk+of+serious+pneumonia.&amp;publication_year=2013&amp;journal=Thorax&amp;pages=1029-1036&amp;doi=10.1136%2Fthoraxjnl-2012-202872&amp;pmid=24130228" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. <em>Thorax</em> 2011;66:699-708.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/thx.2011.160028" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21602540/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000292916400013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+of+fractures+with+inhaled+corticosteroids+in+COPD%3A+systematic+review+and+meta-analysis+of+randomised+controlled+trials+and+observational+studies.&amp;publication_year=2011&amp;journal=Thorax&amp;pages=699-708&amp;doi=10.1136%2Fthx.2011.160028&amp;pmid=21602540" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Rabe KF, Martinez FJ, Ferguson GT, et al. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: the ETHOS study protocol. <em>Respir Med</em> 2019;158:59-66.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.rmed.2019.08.010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31605923/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000500951100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+III+study+of+triple+therapy+with+budesonide%2Fglycopyrrolate%2Fformoterol+fumarate+metered+dose+inhaler+320%2F18%2F9.6%E2%80%AF%CE%BCg+and+160%2F18%2F9.6%E2%80%AF%CE%BCg+using+co-suspension+delivery+technology+in+moderate-to-very+severe+COPD%3A+the+ETHOS+study+protocol.&amp;publication_year=2019&amp;journal=Respir+Med&amp;pages=59-66&amp;doi=10.1016%2Fj.rmed.2019.08.010&amp;pmid=31605923" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] trial design has been published previously, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to the regional statistical approach used. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Battisti WP, Wager E, Baltzer L, et al. Good publication practice for communicating company-sponsored medical research: GPP3. <em>Ann Intern Med</em> 2015;163:461-464.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7326/M15-0288" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26259067/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000361365900020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Good+publication+practice+for+communicating+company-sponsored+medical+research%3A+GPP3.&amp;publication_year=2015&amp;journal=Ann+Intern+Med&amp;pages=461-464&amp;doi=10.7326%2FM15-0288&amp;pmid=26259067" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Guideline on statistical principles for clinical trials: addendum on estimands and sensitivity analysis in clinical trials. November 2019 (<a href="https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf">https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=International+Council+for+Harmonisation+of+Technical+Requirements+for+Pharmaceuticals+for+Human+Use+%28ICH%29.+Guideline+on+statistical+principles+for+clinical+trials%3A+addendum+on+estimands+and+sensitivity+analysis+in+clinical+trials.+November+2019+%28https%3A%2F%2Fdatabase.ich.org%2Fsites%2Fdefault%2Ffiles%2FE9-R1_Step4_Guideline_2019_1203.pdf%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Darken P, Nyberg J, Ballal S, Wright D. The attributable estimand: a new approach to account for intercurrent events. <em>Pharm Stat</em> 2020 March 21 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/pst.2019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32198954/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000522719700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+attributable+estimand%3A+a+new+approach+to+account+for+intercurrent+events.&amp;publication_year=2020&amp;journal=Pharm+Stat&amp;doi=10.1002%2Fpst.2019&amp;pmid=32198954" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. <em>N Engl J Med</em> 2007;356:775-789.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_16_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1916046&amp;key=10.1056%2FNEJMoa063070&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17314337/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000244326700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Salmeterol+and+fluticasone+propionate+and+survival+in+chronic+obstructive+pulmonary+disease.&amp;publication_year=2007&amp;journal=N+Engl+J+Med&amp;pages=775-789&amp;doi=10.1056%2FNEJMoa063070&amp;pmid=17314337" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Calverley PMA, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. <em>Thorax</em> 2010;65:719-725.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/thx.2010.136077" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20685748/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000280527600011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cardiovascular+events+in+patients+with+COPD%3A+TORCH+study+results.&amp;publication_year=2010&amp;journal=Thorax&amp;pages=719-725&amp;doi=10.1136%2Fthx.2010.136077&amp;pmid=20685748" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. <em>Lancet</em> 2016;387:1817-1826.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)30069-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27203508/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000375056100030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Fluticasone+furoate+and+vilanterol+and+survival+in+chronic+obstructive+pulmonary+disease+with+heightened+cardiovascular+risk+%28SUMMIT%29%3A+a+double-blind+randomised+controlled+trial.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=1817-1826&amp;doi=10.1016%2FS0140-6736%2816%2930069-1&amp;pmid=27203508" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Suissa S, Ariel A. Triple therapy trials in COPD: a precision medicine opportunity. <em>Eur Respir J</em> 2018;52(6):1801848-1801848.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.01848-2018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30545959/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000454780300023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Triple+therapy+trials+in+COPD%3A+a+precision+medicine+opportunity.&amp;publication_year=2018&amp;journal=Eur+Respir+J&amp;pages=1801848-1801848&amp;doi=10.1183%2F13993003.01848-2018&amp;pmid=30545959" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. <em>Lancet Respir Med</em> 2018;6:117-126.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-2600(18)30006-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29331313/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000424657100019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Predictors+of+exacerbation+risk+and+response+to+budesonide+in+patients+with+chronic+obstructive+pulmonary+disease%3A+a+post-hoc+analysis+of+three+randomised+trials.&amp;publication_year=2018&amp;journal=Lancet+Respir+Med&amp;pages=117-126&amp;doi=10.1016%2FS2213-2600%2818%2930006-7&amp;pmid=29331313" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. <em>Lancet Respir Med</em> 2015;3:435-442.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-2600(15)00106-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25878028/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000355558500020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Blood+eosinophil+counts%2C+exacerbations%2C+and+response+to+the+addition+of+inhaled+fluticasone+furoate+to+vilanterol+in+patients+with+chronic+obstructive+pulmonary+disease%3A+a+secondary+analysis+of+data+from+two+parallel+randomised+controlled+trials.&amp;publication_year=2015&amp;journal=Lancet+Respir+Med&amp;pages=435-442&amp;doi=10.1016%2FS2213-2600%2815%2900106-X&amp;pmid=25878028" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. <em>Am J Respir Crit Care Med</em> 2018;198:329-339.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.201803-0405OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29779416/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000440607200013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+triple+therapy+de-escalation+to+indacaterol%2Fglycopyrronium+in+patients+with+chronic+obstructive+pulmonary+disease+%28SUNSET%29%3A+a+randomized%2C+double-blind%2C+triple-dummy+clinical+trial.&amp;publication_year=2018&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=329-339&amp;doi=10.1164%2Frccm.201803-0405OC&amp;pmid=29779416" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Williams NP, Coombs NA, Johnson MJ, et al. Seasonality, risk factors and burden of community-acquired pneumonia in COPD patients: a population database study using linked health care records. <em>Int J Chron Obstruct Pulmon Dis</em> 2017;12:313-322.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/COPD.S121389" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28176888/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000391912600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Seasonality%2C+risk+factors+and+burden+of+community-acquired+pneumonia+in+COPD+patients%3A+a+population+database+study+using+linked+health+care+records.&amp;publication_year=2017&amp;journal=Int+J+Chron+Obstruct+Pulmon+Dis&amp;pages=313-322&amp;doi=10.2147%2FCOPD.S121389&amp;pmid=28176888" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/383/1"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">383</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">1</span></span> • <span property="datePublished">July 2, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">35</span>-<span property="pageEnd">48</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: June 24, 2020</div><div><b class="core-label">Published in issue</b>: July 2, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/copd" alt="View article keyword COPD" data-interactiontype="article_recirculation_click">COPD</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Klaus F.</span> <span property="familyName">Rabe</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Fernando J.</span> <span property="familyName">Martinez</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Gary T.</span> <span property="familyName">Ferguson</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Chen</span> <span property="familyName">Wang</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Dave</span> <span property="familyName">Singh</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jadwiga A.</span> <span property="familyName">Wedzicha</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Roopa</span> <span property="familyName">Trivedi</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Earl</span> <span property="familyName">St. Rose</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Shaila</span> <span property="familyName">Ballal</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Julie</span> <span property="familyName">McLaren</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Patrick</span> <span property="familyName">Darken</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Magnus</span> <span property="familyName">Aurivillius</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Colin</span> <span property="familyName">Reisner</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Paul</span> <span property="familyName">Dorinsky</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the ETHOS Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, German Center for Lung Research (DZL), Grosshansdorf, Germany (K.F.R.); the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York (F.J.M.); the Pulmonary Research Institute of Southeast Michigan, Farmington Hills (G.T.F.); the National Clinical Research Center for Respiratory Diseases, China–Japan Friendship Hospital, Beijing (C.W.); the Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester (D.S.), and the National Heart and Lung Institute, Imperial College London, London (J.A.W.) — both in the United Kingdom; AstraZeneca, Durham, NC (R.T., P. Dorinsky); AstraZeneca, Morristown, NJ (E.S.R., S.B., P. Darken, C.R.); AstraZeneca, Gaithersburg, MD (J.M.); and AstraZeneca, Gothenburg, Sweden (M.A.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Rabe at LungenClinic Grosshansdorf, Wöhrendamm 80, 22927 Grosshansdorf, Germany, or at <a href="mailto:k.f.rabe@lungenclinic.de">k.f.rabe@lungenclinic.de</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of the ETHOS trial investigators is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">448</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa1916046" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="08ff5849-c87d-a182-4003-e20be0646dad"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84628946" style="display:inline-block;">
                <img alt="Article has an altmetric score of 304" src="https://badges.altmetric.com/?size=320&amp;score=304&amp;types=mabvctfd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84628946">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_08ff5849-c87d-a182-4003-e20be0646dad" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84628946&amp;tab=news">
          Picked up by <b>26</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84628946&amp;tab=blogs">
          Blogged by <b>5</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84628946&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84628946&amp;tab=twitter">
          Posted by <b>115</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84628946&amp;tab=patents">
          Referenced in <b>4</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84628946&amp;tab=facebook">
          On <b>4</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84628946&amp;tab=video">
          On <b>1</b> videos
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=84628946&amp;tab=guidelines">
          Referenced in <b>4</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>516</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6373973c9f179-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa1916046"> <input type="hidden" name="downloadFileName" value="csp_383_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1916046%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-1%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="448" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">A. Calderón-Montero, </li><li class="list-inline-item cited-by__entry__author">M. García Fernández, </li><li class="list-inline-item cited-by__entry__author">M.E. García-Velasco, </li><li class="list-inline-item cited-by__entry__author">M. Joshi, </li><li class="list-inline-item cited-by__entry__author">K. Khan, </li><li class="list-inline-item cited-by__entry__author">C. Calderón-Ferrer, </li><li class="list-inline-item cited-by__entry__author">M. Núñez-Núñez, </li></ul><span class="cited-by__entry__title">Effect of triple inhaled therapy on cardiovascular and all-cause mortality compared with dual inhaled therapy in COPD: A systematic review and meta-analysis, </span><span class="cited-by__entry__series-title">Medicina de Familia. SEMERGEN, </span><span class="cited-by__entry__volume"><strong>51</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(102478), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.semerg.2025.102478" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.semerg.2025.102478</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.semerg.2025.102478" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Leonie Biener, </li><li class="list-inline-item cited-by__entry__author">Janne Carolin Drews, </li><li class="list-inline-item cited-by__entry__author">Carmen Pizarro, </li><li class="list-inline-item cited-by__entry__author">Max Jonathan Stumpf, </li><li class="list-inline-item cited-by__entry__author">Nadjib Schahab, </li><li class="list-inline-item cited-by__entry__author">Christian Schaefer, </li><li class="list-inline-item cited-by__entry__author">Dirk Skowasch, </li></ul><span class="cited-by__entry__title">(Pre-) atherosclerotic vessel changes in patients with chronic obstructive pulmonary disease and eosinophilia, </span><span class="cited-by__entry__series-title">BMC Pulmonary Medicine, </span><span class="cited-by__entry__volume"><strong>25</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s12890-025-03720-y" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s12890-025-03720-y</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s12890-025-03720-y" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Marco Vanetti, </li><li class="list-inline-item cited-by__entry__author">Dina Visca, </li><li class="list-inline-item cited-by__entry__author">Francesco Ardesi, </li><li class="list-inline-item cited-by__entry__author">Martina Zappa, </li><li class="list-inline-item cited-by__entry__author">Patrizia Pignatti, </li><li class="list-inline-item cited-by__entry__author">Antonio Spanevello, </li></ul><span class="cited-by__entry__title">Eosinophils in chronic obstructive pulmonary disease, </span><span class="cited-by__entry__series-title">Therapeutic Advances in Respiratory Disease, </span><span class="cited-by__entry__volume"><strong>19</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1177/17534666251335800" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1177/17534666251335800</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1177/17534666251335800" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Elsa Ben Hamou-Kuijpers, </li><li class="list-inline-item cited-by__entry__author">Simon Couillard, </li></ul><span class="cited-by__entry__title">Smoking gun: when COPD therapies fail current smokers, </span><span class="cited-by__entry__series-title">Thorax, </span><span class="cited-by__entry__page-range">(thorax-2025-223459), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1136/thorax-2025-223459" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1136/thorax-2025-223459</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1136/thorax-2025-223459" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Wang&nbsp;Chun Kwok, </li><li class="list-inline-item cited-by__entry__author">Chung&nbsp;Ki Tsui, </li><li class="list-inline-item cited-by__entry__author">Sze&nbsp;Him&nbsp;Isaac Leung, </li><li class="list-inline-item cited-by__entry__author">Shuk&nbsp;Man Ngai, </li><li class="list-inline-item cited-by__entry__author">David&nbsp;Chi&nbsp;Leung Lam, </li><li class="list-inline-item cited-by__entry__author">Mary&nbsp;Sau&nbsp;Man Ip, </li><li class="list-inline-item cited-by__entry__author">James&nbsp;Chung&nbsp;Man Ho, </li></ul><span class="cited-by__entry__title">Dose of Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease and Risks of Osteoporosis or Fracture—A Systematic Review and Meta‐Analysis, </span><span class="cited-by__entry__series-title">The Clinical Respiratory Journal, </span><span class="cited-by__entry__volume"><strong>19</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/crj.70086" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/crj.70086</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/crj.70086" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Dave Singh, </li><li class="list-inline-item cited-by__entry__author">Andrew Higham, </li><li class="list-inline-item cited-by__entry__author">Alexander G. Mathioudakis, </li><li class="list-inline-item cited-by__entry__author">Augusta Beech, </li></ul><span class="cited-by__entry__title">Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments, </span><span class="cited-by__entry__series-title">Drugs, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s40265-025-02188-8" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s40265-025-02188-8</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s40265-025-02188-8" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Dave Singh, </li><li class="list-inline-item cited-by__entry__author">Mona Bafadhel, </li><li class="list-inline-item cited-by__entry__author">Niki Arya, </li><li class="list-inline-item cited-by__entry__author">Jonathan Marshall, </li><li class="list-inline-item cited-by__entry__author">Himanshu Parikh, </li><li class="list-inline-item cited-by__entry__author">Dobrawa Kisielewicz, </li><li class="list-inline-item cited-by__entry__author">Charlotta Movitz, </li><li class="list-inline-item cited-by__entry__author">Karin Bowen, </li><li class="list-inline-item cited-by__entry__author">Mehul Patel, </li></ul><span class="cited-by__entry__title">Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β2-agonist: post-hoc analyses of KRONOS, </span><span class="cited-by__entry__series-title">Respiratory Research, </span><span class="cited-by__entry__volume"><strong>26</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s12931-025-03234-5" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s12931-025-03234-5</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s12931-025-03234-5" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">William A E Parker, </li><li class="list-inline-item cited-by__entry__author">Josefin Sundh, </li><li class="list-inline-item cited-by__entry__author">Jonas Oldgren, </li><li class="list-inline-item cited-by__entry__author">Pontus Andell, </li><li class="list-inline-item cited-by__entry__author">Christian Reitan, </li><li class="list-inline-item cited-by__entry__author">Tomas Jernberg, </li><li class="list-inline-item cited-by__entry__author">Robin Hofmann, </li><li class="list-inline-item cited-by__entry__author">Moman A Mohammad, </li><li class="list-inline-item cited-by__entry__author">David Erlinge, </li><li class="list-inline-item cited-by__entry__author">Axel Akerblom, </li><li class="list-inline-item cited-by__entry__author">Sofia Sederstam Lawesson, </li><li class="list-inline-item cited-by__entry__author">Kyriakos V Konstantinidis, </li><li class="list-inline-item cited-by__entry__author">Johan Lindbäck, </li><li class="list-inline-item cited-by__entry__author">Christer Janson, </li><li class="list-inline-item cited-by__entry__author">Anna Björkenheim, </li><li class="list-inline-item cited-by__entry__author">Nadir Elamin, </li><li class="list-inline-item cited-by__entry__author">Hannah McMellon, </li><li class="list-inline-item cited-by__entry__author">Bethany Moyle, </li><li class="list-inline-item cited-by__entry__author">Mehul Patel, </li><li class="list-inline-item cited-by__entry__author">Jad El-Khoury, </li><li class="list-inline-item cited-by__entry__author">Raulin Surujbally, </li><li class="list-inline-item cited-by__entry__author">Robert F Storey, </li><li class="list-inline-item cited-by__entry__author">Stefan K James, </li></ul><span class="cited-by__entry__title">Prevalence of microspirometry-detected chronic obstructive pulmonary disease in two European cohorts of patients hospitalised for acute myocardial infarction: a cross-sectional study, </span><span class="cited-by__entry__series-title">BMJ Open, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(e097851), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1136/bmjopen-2024-097851" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1136/bmjopen-2024-097851</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1136/bmjopen-2024-097851" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Suzanne Lareau, </li><li class="list-inline-item cited-by__entry__author">Richard ZuWallack, </li><li class="list-inline-item cited-by__entry__author">Linda Nici, </li></ul><span class="cited-by__entry__title">Increasing Quality and Quantity of Life in Individuals with Chronic Obstructive Pulmonary Disease: A Narrative Review with an Emphasis on Pulmonary Rehabilitation, </span><span class="cited-by__entry__series-title">Life, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(750), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/life15050750" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/life15050750</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/life15050750" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">SUPRAJA A., </li><li class="list-inline-item cited-by__entry__author">GUNDAWAR RAVI, </li><li class="list-inline-item cited-by__entry__author">TANVI PAINGINKAR, </li><li class="list-inline-item cited-by__entry__author">GIRISH PAI K., </li><li class="list-inline-item cited-by__entry__author">VIRENDRA S. LIGADE, </li><li class="list-inline-item cited-by__entry__author">K. SREEDHARA RANGANATH PAI, </li><li class="list-inline-item cited-by__entry__author">VASANTHARAJU SG, </li><li class="list-inline-item cited-by__entry__author">MUDDUKRISHNA BS, </li></ul><span class="cited-by__entry__title">AN OVERVIEW OF COPD: ITS ADVANCED THERAPEUTIC MANAGEMENT AND CHALLENGES FOR DRUG RELEASE AT THE TARGETED SITE, </span><span class="cited-by__entry__series-title">International Journal of Applied Pharmaceutics, </span><span class="cited-by__entry__page-range">(28-54), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.22159/ijap.2025v17i3.53675" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.22159/ijap.2025v17i3.53675</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.22159/ijap.2025v17i3.53675" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1916046%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-1%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1916046" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1916046" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1916046.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1916046_f1.jpg"><img src="/cms/10.1056/NEJMoa1916046/asset/7146d115-33d7-4ddc-b19a-30372b6c95cb/assets/images/large/nejmoa1916046_f1.jpg" height="1816" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, and Treatment.</div><div class="notes"><div role="doc-footnote">Shown is the distribution of patients during screening, randomization, and treatment. The patients in the 320-μg–budesonide triple-therapy group received twice-daily doses of 320 μg of budesonide, 18 μg of glycopyrrolate, and 9.6 μg of formoterol fumarate; those in the 160-μg–budesonide triple-therapy group received twice-daily doses of 160 μg of budesonide, 18 μg of glycopyrrolate, and 9.6 μg of formoterol fumarate; those in the glycopyrrolate–formoterol group received twice-daily doses of 18 μg of glycopyrrolate and 9.6 μg of formoterol fumarate; and those in the budesonide–formoterol group received twice-daily doses of 320 μg of budesonide and 9.6 μg of formoterol fumarate. The intention-to-treat population included all patients who underwent randomization and received any amount of trial treatment. The modified intention-to-treat population included all patients in the intention-to-treat population with postrandomization data obtained before discontinuation of treatment. Any data collected after completion of, or discontinuation of, the assigned trial regimen was excluded from the modified intention-to-treat analysis but included in the intention-to-treat analysis. The safety population included all patients who underwent randomization, received any amount of treatment, and had a postrandomization safety assessment. Forty-four patients were excluded from all analysis populations because of overlapping treatment exposure from participating multiple times in the same study or participating concurrently in another study. An additional 20 patients were not included in the modified intention-to-treat population (8509 patients) because they had multiple enrollments, although with nonoverlapping treatment exposure (19 patients) or because of administrative reasons (1 patient); these patients were included in the safety population (8529 patients).</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1916046_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1916046_f2.jpg"><img src="/cms/10.1056/NEJMoa1916046/asset/e929749f-b349-4e07-80fc-26f5fac1d565/assets/images/large/nejmoa1916046_f2.jpg" height="3438" width="2303" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Estimates of the Cumulative Incidence of Moderate or Severe COPD Exacerbations and Death from Any Cause in Time-to-First-Event Analyses.</div><div class="notes"><div role="doc-footnote">Panel A shows the time to the first moderate or severe exacerbation of chronic obstructive pulmonary disease (COPD). The analysis was performed in the modified intention-to-treat population with the use of an efficacy estimand, which included only data obtained from patients while they were receiving a trial treatment. Panel B shows the time to death from any cause. The analysis was performed in the intention-to-treat population with the use of a treatment policy estimand, which included all observed data obtained from the patients regardless of whether they continued to receive their assigned treatment. The inset shows the same data on an enlarged y axis. Tick marks indicate the time of data censoring.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1916046_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1916046_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1916046/asset/480ba503-31fd-4aa4-9267-057bd102629f/assets/images/large/nejmoa1916046_t1.jpg" height="2179" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">320-μg–Budesonide Triple Therapy <br>(N=2137)</th><th class="txxx-borders">160-μg–Budesonide Triple Therapy <br>(N=2121)</th><th class="txxx-borders">Glycopyrrolate–Formoterol<br>(N=2120)</th><th class="txxr-borders">Budesonide–Formoterol<br>(N=2131)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">64.6±7.6</td><td class="xxxx-borders shading">64.6±7.6</td><td class="xxxx-borders shading">64.8±7.6</td><td class="xxxr-borders shading">64.6±7.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders">1260 (59.0)</td><td class="xxxx-borders">1298 (61.2)</td><td class="xxxx-borders">1244 (58.7)</td><td class="xxxr-borders">1279 (60.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Current smoker — no. (%)</td><td class="xxxx-borders shading">910 (42.6)</td><td class="xxxx-borders shading">865 (40.8)</td><td class="xxxx-borders shading">856 (40.4)</td><td class="xxxr-borders shading">864 (40.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Pack-years of smoking</td><td class="xxxx-borders">47.0±25.1</td><td class="xxxx-borders">47.9±25.8</td><td class="xxxx-borders">48.4±26.5</td><td class="xxxr-borders">47.1±26.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">COPD exacerbations in the past 12 mo — no.</td><td class="xxxx-borders shading">1.7±0.8</td><td class="xxxx-borders shading">1.7±0.9</td><td class="xxxx-borders shading">1.7±0.8</td><td class="xxxr-borders shading">1.7±0.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">0 Moderate or severe — no. (%)</td><td class="xxxx-borders">2 (0.1)</td><td class="xxxx-borders">2 (0.1)</td><td class="xxxx-borders">2 (0.1)</td><td class="xxxr-borders">2 (0.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1 Moderate or severe — no. (%)</td><td class="xxxx-borders shading">940 (44.0)</td><td class="xxxx-borders shading">932 (43.9)</td><td class="xxxx-borders shading">907 (42.8)</td><td class="xxxr-borders shading">912 (42.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≥2 Moderate or severe — no. (%)</td><td class="xxxx-borders">1195 (55.9)</td><td class="xxxx-borders">1187 (56.0)</td><td class="xxxx-borders">1211 (57.1)</td><td class="xxxr-borders">1217 (57.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥1 Severe — no. (%)</td><td class="xxxx-borders shading">451 (21.1)</td><td class="xxxx-borders shading">463 (21.8)</td><td class="xxxx-borders shading">429 (20.2)</td><td class="xxxr-borders shading">458 (21.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Blood eosinophil count</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median (range) — cells/mm<sup>3</sup></td><td class="xxxx-borders shading">165 (0–2510)</td><td class="xxxx-borders shading">167 (5–1590)</td><td class="xxxx-borders shading">170 (5–2305)</td><td class="xxxr-borders shading">167 (0–2430)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≥150 cells/mm<sup>3</sup> — no. (%)</td><td class="xxxx-borders">1277 (59.8)</td><td class="xxxx-borders">1258 (59.3)</td><td class="xxxx-borders">1272 (60.0)</td><td class="xxxr-borders">1294 (60.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥300 cells/mm<sup>3</sup> — no. (%)</td><td class="xxxx-borders shading">310 (14.5)</td><td class="xxxx-borders shading">318 (15.0)</td><td class="xxxx-borders shading">293 (13.8)</td><td class="xxxr-borders shading">333 (15.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">FEV<sub>1</sub> after administration of albuterol — % of the predicted normal value</td><td class="xxxx-borders">43.6±10.3</td><td class="xxxx-borders">43.1±10.4</td><td class="xxxx-borders">43.5±10.2</td><td class="xxxr-borders">43.4±10.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">50 to &lt;80% of the predicted normal value: moderate COPD — no. (%)</td><td class="xxxx-borders shading">613 (28.7)</td><td class="xxxx-borders shading">604 (28.5)</td><td class="xxxx-borders shading">596 (28.1)</td><td class="xxxr-borders shading">614 (28.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">30 to &lt;50% of the predicted normal value: severe COPD — no. (%)</td><td class="xxxx-borders">1305 (61.1)</td><td class="xxxx-borders">1270 (59.9)</td><td class="xxxx-borders">1293 (61.0)</td><td class="xxxr-borders">1283 (60.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">&lt;30% of the predicted normal value: very severe COPD — no. (%)</td><td class="xxxx-borders shading">217 (10.2)</td><td class="xxxx-borders shading">245 (11.6)</td><td class="xxxx-borders shading">229 (10.8)</td><td class="xxxr-borders shading">233 (10.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Change in FEV<sub>1</sub> from before to after administration of albuterol — ml</td><td class="xxxx-borders">146.3±158.0</td><td class="xxxx-borders">144.4±151.7</td><td class="xxxx-borders">148.7±151.1</td><td class="xxxr-borders">142.3±144.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Bronchodilator reversibility — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">657 (30.7)</td><td class="xxxx-borders shading">631 (29.8)</td><td class="xxxx-borders shading">669 (31.6)</td><td class="xxxr-borders shading">654 (30.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Use of inhaled glucocorticoid at screening — no. (%)</td><td class="xxxx-borders">1706 (79.8)</td><td class="xxxx-borders">1729 (81.5)</td><td class="xxxx-borders">1707 (80.5)</td><td class="xxxr-borders">1704 (80.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">COPD Assessment Test score<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xbxx-borders shading">19.7±6.5</td><td class="xbxx-borders shading">19.6±6.6</td><td class="xbxx-borders shading">19.5±6.6</td><td class="xbxr-borders shading">19.5±6.5</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. The modified intention-to-treat population included all patients who underwent randomization, received any amount of trial treatment, and had postrandomization data obtained before discontinuation of treatment. The 320-μg–budesonide triple-therapy group received twice daily doses of 320 μg of budesonide, 18 μg of glycopyrrolate, and 9.6 μg of formoterol fumarate; the 160-μg–budesonide triple-therapy group received twice-daily doses of 160 μg of budesonide, 18 μg of glycopyrrolate, and 9.6 μg of formoterol fumarate; the glycopyrrolate–formoterol group received twice-daily doses of 18 μg of glycopyrrolate and 9.6 μg of formoterol fumarate; and the budesonide–formoterol group received twice-daily doses of 320 μg of budesonide and 9.6 μg of formoterol fumarate. The doses of glycopyrrolate and formoterol fumarate are equivalent to 14.4 μg of glycopyrronium and 10 μg of formoterol fumarate dihydrate, respectively. COPD denotes chronic obstructive pulmonary disease, and FEV<sub>1</sub> forced expiratory volume in 1 second.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Bronchodilator reversibility was defined as an increase in FEV<sub>1</sub> of at least 12% and at least 200 ml after administration of albuterol.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Scores on the COPD Assessment Test range from 0 to 40, with higher scores indicating more symptoms; the minimum clinically important difference in score is 2 points.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic Characteristics of the Patients at Baseline (Modified Intention-to-Treat Population).<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1916046_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1916046_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1916046/asset/60daa192-9199-492c-9bf2-9699047bd093/assets/images/large/nejmoa1916046_t2.jpg" height="3194" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="xxxx-borders" data-xml-align="left">End Point</th><th class="xxxx-borders">320-μg–Budesonide<br>Triple Therapy<br>(N=2137)</th><th class="xxxx-borders">160-μg–Budesonide<br>Triple Therapy<br>(N=2121)</th><th class="xxxx-borders">Glycopyrrolate–<br>Formoterol<br>(N=2120)</th><th class="xxxx-borders">Budesonide–<br>Formoterol<br>(N=2131)</th></tr></thead><tbody><tr data-type="row"><td class="xxxx-borders hanging03 shading"><b>Primary end point</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03" data-xml-align="left">Primary analysis: model-estimated annual rate of moderate or severe COPD exacerbations</td><td class="xxxx-borders">1.08</td><td class="xxxx-borders">1.07</td><td class="xxxx-borders">1.42</td><td class="xxxx-borders">1.24</td></tr><tr data-type="row"><td class="xxxx-borders hanging13 shading">320-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">Rate ratio for moderate or severe exacerbations (95% CI)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">1.00 (0.91–1.10)</td><td class="xxxx-borders">0.76 (0.69–0.83)</td><td class="xxxx-borders">0.87 (0.79–0.95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">P value<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">0.003</td></tr><tr data-type="row"><td class="xxxx-borders hanging13">160-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">Rate ratio for moderate or severe exacerbations (95% CI)</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">0.75 (0.69–0.83)</td><td class="xxxx-borders shading">0.86 (0.79–0.95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">P value</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">0.002</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03 shading" data-xml-align="left">Secondary analysis: model-estimated annual rate of moderate or severe COPD exacerbations (attributable estimand)<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">1.25</td><td class="xxxx-borders shading">1.23</td><td class="xxxx-borders shading">1.63</td><td class="xxxx-borders shading">1.47</td></tr><tr data-type="row"><td class="xxxx-borders hanging13">320-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">Rate ratio for moderate or severe exacerbations (95% CI)</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">1.01 (0.94–1.10)</td><td class="xxxx-borders shading">0.76 (0.71–0.83)</td><td class="xxxx-borders shading">0.85 (0.78–0.92)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">P value<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">—</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&lt;0.001</td></tr><tr data-type="row"><td class="xxxx-borders hanging13 shading">160-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">Rate ratio for moderate or severe exacerbations (95% CI)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">0.75 (0.70–0.82)</td><td class="xxxx-borders">0.84 (0.77–0.90)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">P value</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&lt;0.001</td></tr><tr data-type="row"><td class="xxxx-borders hanging03"><b>Secondary exacerbation and mortality end points</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">Time to first moderate or severe COPD exacerbation over 52 wk</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">Patients with exacerbations — no. (%)</td><td class="xxxx-borders">1026 (48.0)</td><td class="xxxx-borders">1013 (47.8)</td><td class="xxxx-borders">1056 (49.8)</td><td class="xxxx-borders">1085 (50.9)</td></tr><tr data-type="row"><td class="xxxx-borders hanging13 shading">320-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">Hazard ratio for moderate or severe exacerbation (95% CI)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">1.02 (0.93–1.11)</td><td class="xxxx-borders">0.88 (0.81–0.96)</td><td class="xxxx-borders">0.89 (0.81–0.97)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">P value<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">0.004</td><td class="xxxx-borders shading">0.006</td></tr><tr data-type="row"><td class="xxxx-borders hanging13">160-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">Hazard ratio for moderate or severe exacerbation (95% CI)</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">0.87 (0.79–0.94)</td><td class="xxxx-borders shading">0.87 (0.80–0.95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">P value</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.001</td><td class="xxxx-borders">0.002</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging03 shading" data-xml-align="left">Model-estimated annual rate of severe COPD exacerbations</td><td class="xxxx-borders shading">0.13</td><td class="xxxx-borders shading">0.14</td><td class="xxxx-borders shading">0.15</td><td class="xxxx-borders shading">0.16</td></tr><tr data-type="row"><td class="xxxx-borders hanging13">320-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23 shading" data-xml-align="left">Rate ratio for severe exacerbations (95% CI)</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">0.96 (0.78–1.17)</td><td class="xxxx-borders shading">0.84 (0.69–1.03)</td><td class="xxxx-borders shading">0.80 (0.66–0.97)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">P value<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">—</td><td class="xxxx-borders">0.09</td><td class="xxxx-borders">0.02</td></tr><tr data-type="row"><td class="xxxx-borders hanging13 shading">160-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">Rate ratio for severe exacerbations (95% CI)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">0.88 (0.72–1.08)</td><td class="xxxx-borders">0.83 (0.69–1.01)</td></tr><tr data-type="row"><td class="xxxx-borders hanging03 shading">Time to death from any cause over 52 wk (treatment policy estimand)<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging13" data-xml-align="left">Patient deaths — no. (%)</td><td class="xxxx-borders">28 (1.3)</td><td class="xxxx-borders">39 (1.8)</td><td class="xxxx-borders">49 (2.3)</td><td class="xxxx-borders">34 (1.6)</td></tr><tr data-type="row"><td class="xxxx-borders hanging13 shading">320-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">Hazard ratio for death (95% CI)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">0.69 (0.42–1.13)</td><td class="xxxx-borders">0.54 (0.34–0.87)</td><td class="xxxx-borders">0.78 (0.47–1.30)</td></tr><tr data-type="row"><td class="xxxx-borders hanging13 shading">160-μg–Budesonide triple therapy vs. comparators</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging23" data-xml-align="left">Hazard ratio for death (95% CI)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">0.79 (0.52–1.20)</td><td class="xxxx-borders">1.13 (0.72–1.80)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Efficacy analyses were performed in the modified intention-to-treat population with the use of an efficacy estimand, unless otherwise specified; the efficacy estimand included only data obtained from patients while they were receiving a trial treatment. The annual rate is the estimated mean number of exacerbations per patient per year. Additional secondary end points are reported in Table S4.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Comparisons between the 320-μg–budesonide triple-therapy group and the 160-μg–budesonide triple-therapy group were not included in the testing hierarchy and thus no P values are provided.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">The secondary analysis of the primary end point was performed with an attributable estimand, where data obtained after treatment discontinuation due to lack of efficacy or adverse events were imputed as “poor responses.”</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">The analysis of time to death from any cause over 52 weeks was performed in the intention-to-treat population (all patients who underwent randomization and received any amount of trial treatment) with the use of a treatment policy estimand, which included all observed data from the patients regardless of whether they continued to receive their assigned treatment.</div></div></div></figcaption></a><figcaption><div class="caption">Efficacy End Points.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1916046_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1916046_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1916046/asset/b3867119-d5c8-4533-ac0e-1e537cc6d716/assets/images/large/nejmoa1916046_t3.jpg" height="1435" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="2"><span>320-μg–Budesonide Triple Therapy<br>(N=2144)</span></th><th class="txxx-borders" colspan="2"><span>160-μg–Budesonide Triple Therapy<br>(N=2124)</span></th><th class="txxx-borders" colspan="2"><span>Glycopyrrolate–Formoterol<br>(N=2125)</span></th><th class="txxr-borders" colspan="2"><span>Budesonide–Formoterol<br>(N=2136)</span></th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">no. of patients (%)</th><th class="xxxx-borders">no. of events<br>(no. per 1000 patient-yr)</th><th class="xxxx-borders">no. of patients (%)</th><th class="xxxx-borders">no. of events<br>(no. per 1000 patient-yr)</th><th class="xxxx-borders">no. of patients (%)</th><th class="xxxx-borders">no. of events<br>(no. per 1000 patient-yr)</th><th class="xxxx-borders">no. of patients (%)</th><th class="xxxr-borders">no. of events<br>(no. per 1000 patient-yr)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">1368 (63.8)</td><td class="xxxx-borders shading">4527 (2388.4)</td><td class="xxxx-borders shading">1356 (63.8)</td><td class="xxxx-borders shading">4382 (2318.7)</td><td class="xxxx-borders shading">1312 (61.7)</td><td class="xxxx-borders shading">4074 (2301.7)</td><td class="xxxx-borders shading">1377 (64.5)</td><td class="xxxr-borders shading">4746 (2587.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serious adverse events</td><td class="xxxx-borders">426 (19.9)</td><td class="xxxx-borders">664 (350.3)</td><td class="xxxx-borders">445 (21.0)</td><td class="xxxx-borders">681 (360.3)</td><td class="xxxx-borders">433 (20.4)</td><td class="xxxx-borders">639 (361.0)</td><td class="xxxx-borders">440 (20.6)</td><td class="xxxr-borders">653 (355.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse events that led to early discontinuation</td><td class="xxxx-borders shading">119 (5.6)</td><td class="xxxx-borders shading">150 (79.1)</td><td class="xxxx-borders shading">112 (5.3)</td><td class="xxxx-borders shading">146 (77.3)</td><td class="xxxx-borders shading">146 (6.9)</td><td class="xxxx-borders shading">187 (105.7)</td><td class="xxxx-borders shading">140 (6.6)</td><td class="xxxr-borders shading">160 (87.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Confirmed major adverse cardiovascular event<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">31 (1.4)</td><td class="xxxx-borders">32 (16.9)</td><td class="xxxx-borders">30 (1.4)</td><td class="xxxx-borders">31 (16.4)</td><td class="xxxx-borders">44 (2.1)</td><td class="xxxx-borders">47 (26.6)</td><td class="xxxx-borders">23 (1.1)</td><td class="xxxr-borders">24 (13.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Confirmed pneumonia<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">90 (4.2)</td><td class="xxxx-borders shading">93 (49.1)</td><td class="xxxx-borders shading">75 (3.5)</td><td class="xxxx-borders shading">78 (41.3)</td><td class="xxxx-borders shading">48 (2.3)</td><td class="xxxx-borders shading">51 (28.8)</td><td class="xxxx-borders shading">96 (4.5)</td><td class="xxxr-borders shading">106 (57.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Deaths from any cause during treatment period</td><td class="xxxx-borders">20 (0.9)</td><td class="xxxx-borders">19 (10.0)<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">28 (1.3)</td><td class="xxxx-borders">28 (14.8)</td><td class="xxxx-borders">35 (1.6)</td><td class="xxxx-borders">35 (19.8)</td><td class="xxxx-borders">29 (1.4)</td><td class="xxxr-borders">29 (15.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Adverse events that occurred in ≥3% of patients overall</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders">227 (10.6)</td><td class="xxxx-borders">290 (153.0)</td><td class="xxxx-borders">239 (11.3)</td><td class="xxxx-borders">315 (166.7)</td><td class="xxxx-borders">199 (9.4)</td><td class="xxxx-borders">255 (144.1)</td><td class="xxxx-borders">234 (11.0)</td><td class="xxxr-borders">331 (180.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">COPD</td><td class="xxxx-borders shading">203 (9.5)</td><td class="xxxx-borders shading">256 (135.1)</td><td class="xxxx-borders shading">221 (10.4)</td><td class="xxxx-borders shading">263 (139.2)</td><td class="xxxx-borders shading">219 (10.3)</td><td class="xxxx-borders shading">268 (151.4)</td><td class="xxxx-borders shading">242 (11.3)</td><td class="xxxr-borders shading">300 (163.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders">123 (5.7)</td><td class="xxxx-borders">149 (78.6)</td><td class="xxxx-borders">137 (6.5)</td><td class="xxxx-borders">176 (93.1)</td><td class="xxxx-borders">102 (4.8)</td><td class="xxxx-borders">129 (72.9)</td><td class="xxxx-borders">115 (5.4)</td><td class="xxxr-borders">154 (83.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pneumonia</td><td class="xxxx-borders shading">98 (4.6)</td><td class="xxxx-borders shading">101 (53.3)</td><td class="xxxx-borders shading">85 (4.0)</td><td class="xxxx-borders shading">93 (49.2)</td><td class="xxxx-borders shading">61 (2.9)</td><td class="xxxx-borders shading">66 (37.3)</td><td class="xxxx-borders shading">107 (5.0)</td><td class="xxxr-borders shading">117 (63.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Bronchitis</td><td class="xbxx-borders">66 (3.1)</td><td class="xbxx-borders">74 (39.0)</td><td class="xbxx-borders">68 (3.2)</td><td class="xbxx-borders">76 (40.2)</td><td class="xbxx-borders">76 (3.6)</td><td class="xbxx-borders">81 (45.8)</td><td class="xbxx-borders">69 (3.2)</td><td class="xbxr-borders">83 (45.2)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">The safety population included all patients who underwent randomization, received treatment, and had any postrandomization safety assessment.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Confirmation was obtained from an independent clinical end-point committee.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">A total of 20 patients in the 320-μg–budesonide triple-therapy group had adverse events while they were receiving treatment that were linked to an outcome of death; however, death in 1 patient was adjudicated on the basis of a post-treatment adverse event and therefore was not included in the calculation of the event rate in the on-treatment analysis.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events during the 52-Week Treatment Period (Safety Population).<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1916046_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa1916046</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Global Initiative for Chronic Obstructive Lung Disease. 2020 Report: global strategy for prevention, diagnosis and management of COPD (<a href="https://goldcopd.org/gold-reports/">https://goldcopd.org/gold-reports/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Global+Initiative+for+Chronic+Obstructive+Lung+Disease.+2020+Report%3A+global+strategy+for+prevention%2C+diagnosis+and+management+of+COPD+%28https%3A%2F%2Fgoldcopd.org%2Fgold-reports%2F%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r1-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and reduce or eliminate exacerbations, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] LAMA–LABA or inhaled glucocorticoid–LABA. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] up to inhaled glucocorticoid–LABA therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] as with the current GOLD recommendations. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. <em>Lancet Respir Med</em> 2018;6:747-758.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-2600(18)30327-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30232048/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000445806700019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Triple+therapy+with+budesonide%2Fglycopyrrolate%2Fformoterol+fumarate+with+co-suspension+delivery+technology+versus+dual+therapies+in+chronic+obstructive+pulmonary+disease+%28KRONOS%29%3A+a+double-blind%2C+parallel-group%2C+multicentre%2C+phase+3+randomised+controlled+trial.&amp;publication_year=2018&amp;journal=Lancet+Respir+Med&amp;pages=747-758&amp;doi=10.1016%2FS2213-2600%2818%2930327-8&amp;pmid=30232048" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] quality of life than dual therapies </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] had an exacerbation in the preceding year. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] Lung Disease (KRONOS) trial (1.3 to 1.9%), </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. <em>Am J Respir Crit Care Med</em> 2017;196:438-446.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.201703-0449OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28375647/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000407532700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=FULFIL+trial%3A+once-daily+triple+therapy+for+patients+with+chronic+obstructive+pulmonary+disease.&amp;publication_year=2017&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=438-446&amp;doi=10.1164%2Frccm.201703-0449OC&amp;pmid=28375647" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. <em>N Engl J Med</em> 2018;378:1671-1680.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_5_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1916046&amp;key=10.1056%2FNEJMoa1713901&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29668352/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000431218600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Once-daily+single-inhaler+triple+versus+dual+therapy+in+patients+with+COPD.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=1671-1680&amp;doi=10.1056%2FNEJMoa1713901&amp;pmid=29668352" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] quality of life than dual therapies </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] vs. umeclidinium–vilanterol). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] the IMPACT, TRILOGY, and TRIBUTE trials. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] trials involving patients with COPD, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. <em>Lancet</em> 2018;391:1076-1084.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)30206-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29429593/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000427585100026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Extrafine+inhaled+triple+therapy+versus+dual+bronchodilator+therapy+in+chronic+obstructive+pulmonary+disease+%28TRIBUTE%29%3A+a+double-blind%2C+parallel+group%2C+randomised+controlled+trial.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=1076-1084&amp;doi=10.1016%2FS0140-6736%2818%2930206-X&amp;pmid=29429593" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] quality of life than dual therapies </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the IMPACT, TRILOGY, and TRIBUTE trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β<sub>2</sub>-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. <em>Lancet</em> 2016;388:963-973.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)31354-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27598678/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000382524400026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Single+inhaler+triple+therapy+versus+inhaled+corticosteroid+plus+long-acting+%CE%B22-agonist+therapy+for+chronic+obstructive+pulmonary+disease+%28TRILOGY%29%3A+a+double-blind%2C+parallel+group%2C+randomised+controlled+trial.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=963-973&amp;doi=10.1016%2FS0140-6736%2816%2931354-X&amp;pmid=27598678" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] quality of life than dual therapies </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the IMPACT, TRILOGY, and TRIBUTE trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. <em>Cochrane Database Syst Rev</em> 2014;3:CD010115-CD010115.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24615270/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000333667600029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inhaled+steroids+and+risk+of+pneumonia+for+chronic+obstructive+pulmonary+disease.&amp;publication_year=2014&amp;journal=Cochrane+Database+Syst+Rev&amp;pages=CD010115-CD010115&amp;pmid=24615270" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. <em>N Engl J Med</em> 1997;337:8-14.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_9_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1916046&amp;key=10.1056%2FNEJM199707033370102&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9203425/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1997XH18600002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Use+of+inhaled+corticosteroids+and+the+risk+of+cataracts.&amp;publication_year=1997&amp;journal=N+Engl+J+Med&amp;pages=8-14&amp;doi=10.1056%2FNEJM199707033370102&amp;pmid=9203425" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. <em>Thorax</em> 2013;68:1029-1036.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/thoraxjnl-2012-202872" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24130228/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000326048900011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inhaled+corticosteroids+in+COPD+and+the+risk+of+serious+pneumonia.&amp;publication_year=2013&amp;journal=Thorax&amp;pages=1029-1036&amp;doi=10.1136%2Fthoraxjnl-2012-202872&amp;pmid=24130228" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. <em>Thorax</em> 2011;66:699-708.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/thx.2011.160028" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21602540/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000292916400013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+of+fractures+with+inhaled+corticosteroids+in+COPD%3A+systematic+review+and+meta-analysis+of+randomised+controlled+trials+and+observational+studies.&amp;publication_year=2011&amp;journal=Thorax&amp;pages=699-708&amp;doi=10.1136%2Fthx.2011.160028&amp;pmid=21602540" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Rabe KF, Martinez FJ, Ferguson GT, et al. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: the ETHOS study protocol. <em>Respir Med</em> 2019;158:59-66.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.rmed.2019.08.010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31605923/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000500951100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+III+study+of+triple+therapy+with+budesonide%2Fglycopyrrolate%2Fformoterol+fumarate+metered+dose+inhaler+320%2F18%2F9.6%E2%80%AF%CE%BCg+and+160%2F18%2F9.6%E2%80%AF%CE%BCg+using+co-suspension+delivery+technology+in+moderate-to-very+severe+COPD%3A+the+ETHOS+study+protocol.&amp;publication_year=2019&amp;journal=Respir+Med&amp;pages=59-66&amp;doi=10.1016%2Fj.rmed.2019.08.010&amp;pmid=31605923" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] trial design has been published previously, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to the regional statistical approach used. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Battisti WP, Wager E, Baltzer L, et al. Good publication practice for communicating company-sponsored medical research: GPP3. <em>Ann Intern Med</em> 2015;163:461-464.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7326/M15-0288" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26259067/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000361365900020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Good+publication+practice+for+communicating+company-sponsored+medical+research%3A+GPP3.&amp;publication_year=2015&amp;journal=Ann+Intern+Med&amp;pages=461-464&amp;doi=10.7326%2FM15-0288&amp;pmid=26259067" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Guideline on statistical principles for clinical trials: addendum on estimands and sensitivity analysis in clinical trials. November 2019 (<a href="https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf">https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=International+Council+for+Harmonisation+of+Technical+Requirements+for+Pharmaceuticals+for+Human+Use+%28ICH%29.+Guideline+on+statistical+principles+for+clinical+trials%3A+addendum+on+estimands+and+sensitivity+analysis+in+clinical+trials.+November+2019+%28https%3A%2F%2Fdatabase.ich.org%2Fsites%2Fdefault%2Ffiles%2FE9-R1_Step4_Guideline_2019_1203.pdf%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Darken P, Nyberg J, Ballal S, Wright D. The attributable estimand: a new approach to account for intercurrent events. <em>Pharm Stat</em> 2020 March 21 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/pst.2019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32198954/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000522719700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+attributable+estimand%3A+a+new+approach+to+account+for+intercurrent+events.&amp;publication_year=2020&amp;journal=Pharm+Stat&amp;doi=10.1002%2Fpst.2019&amp;pmid=32198954" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. <em>N Engl J Med</em> 2007;356:775-789.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_16_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1916046&amp;key=10.1056%2FNEJMoa063070&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17314337/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000244326700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Salmeterol+and+fluticasone+propionate+and+survival+in+chronic+obstructive+pulmonary+disease.&amp;publication_year=2007&amp;journal=N+Engl+J+Med&amp;pages=775-789&amp;doi=10.1056%2FNEJMoa063070&amp;pmid=17314337" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Calverley PMA, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. <em>Thorax</em> 2010;65:719-725.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/thx.2010.136077" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20685748/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000280527600011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cardiovascular+events+in+patients+with+COPD%3A+TORCH+study+results.&amp;publication_year=2010&amp;journal=Thorax&amp;pages=719-725&amp;doi=10.1136%2Fthx.2010.136077&amp;pmid=20685748" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. <em>Lancet</em> 2016;387:1817-1826.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)30069-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27203508/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000375056100030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Fluticasone+furoate+and+vilanterol+and+survival+in+chronic+obstructive+pulmonary+disease+with+heightened+cardiovascular+risk+%28SUMMIT%29%3A+a+double-blind+randomised+controlled+trial.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=1817-1826&amp;doi=10.1016%2FS0140-6736%2816%2930069-1&amp;pmid=27203508" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Suissa S, Ariel A. Triple therapy trials in COPD: a precision medicine opportunity. <em>Eur Respir J</em> 2018;52(6):1801848-1801848.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.01848-2018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30545959/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000454780300023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Triple+therapy+trials+in+COPD%3A+a+precision+medicine+opportunity.&amp;publication_year=2018&amp;journal=Eur+Respir+J&amp;pages=1801848-1801848&amp;doi=10.1183%2F13993003.01848-2018&amp;pmid=30545959" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. <em>Lancet Respir Med</em> 2018;6:117-126.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-2600(18)30006-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29331313/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000424657100019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Predictors+of+exacerbation+risk+and+response+to+budesonide+in+patients+with+chronic+obstructive+pulmonary+disease%3A+a+post-hoc+analysis+of+three+randomised+trials.&amp;publication_year=2018&amp;journal=Lancet+Respir+Med&amp;pages=117-126&amp;doi=10.1016%2FS2213-2600%2818%2930006-7&amp;pmid=29331313" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. <em>Lancet Respir Med</em> 2015;3:435-442.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-2600(15)00106-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25878028/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000355558500020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Blood+eosinophil+counts%2C+exacerbations%2C+and+response+to+the+addition+of+inhaled+fluticasone+furoate+to+vilanterol+in+patients+with+chronic+obstructive+pulmonary+disease%3A+a+secondary+analysis+of+data+from+two+parallel+randomised+controlled+trials.&amp;publication_year=2015&amp;journal=Lancet+Respir+Med&amp;pages=435-442&amp;doi=10.1016%2FS2213-2600%2815%2900106-X&amp;pmid=25878028" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. <em>Am J Respir Crit Care Med</em> 2018;198:329-339.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.201803-0405OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29779416/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000440607200013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+triple+therapy+de-escalation+to+indacaterol%2Fglycopyrronium+in+patients+with+chronic+obstructive+pulmonary+disease+%28SUNSET%29%3A+a+randomized%2C+double-blind%2C+triple-dummy+clinical+trial.&amp;publication_year=2018&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=329-339&amp;doi=10.1164%2Frccm.201803-0405OC&amp;pmid=29779416" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Williams NP, Coombs NA, Johnson MJ, et al. Seasonality, risk factors and burden of community-acquired pneumonia in COPD patients: a population database study using linked health care records. <em>Int J Chron Obstruct Pulmon Dis</em> 2017;12:313-322.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/COPD.S121389" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28176888/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000391912600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Seasonality%2C+risk+factors+and+burden+of+community-acquired+pneumonia+in+COPD+patients%3A+a+population+database+study+using+linked+health+care+records.&amp;publication_year=2017&amp;journal=Int+J+Chron+Obstruct+Pulmon+Dis&amp;pages=313-322&amp;doi=10.2147%2FCOPD.S121389&amp;pmid=28176888" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 30, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2026881" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Triple Inhaled Therapy in COPD</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> Malden, Massachusetts</span></div><div><span>Primary Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881718/primary-care-float-physician-opportunity/?query=fjwp&amp;rid=1038">Primary Care Float Physician Opportunity</a></div></div><div class="nejm-widget_item"><div><span> Pennsylvania</span></div><div><span>Faculty</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/850784/a-unique-academic-position-at-a-community-hospital-in-a-thriving-and-diverse-town-/?query=fjwp&amp;rid=423809">A Unique Academic Position at a Community Hospital in a Thriving and Diverse Town!</a></div></div><div class="nejm-widget_item"><div><span> Illinois</span></div><div><span>Surgery, Orthopedic</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/878681/west-illinois-total-joint-orthopedics-850k-base-50k-sign-on-and-150k-student-loan/?query=fjwf&amp;rid=5127">West Illinois Total Joint Orthopedics-850K Base, 50K Sign-On &amp; 150K Student Loan</a></div></div><div class="nejm-widget_item"><div><span> Manassas, Virginia</span></div><div><span>Primary Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886072/primary-care-northern-virginia/?query=fjwf&amp;rid=468039">Primary Care Northern Virginia</a></div></div><div class="nejm-widget_item"><div><span> Denver, Colorado</span></div><div><span>Hospitalist</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/879314/hospitalist-nocturnist/?query=fjwf&amp;rid=220874">Hospitalist - Nocturnist</a></div></div><div class="nejm-widget_item"><div><span> Cleveland, Ohio</span></div><div><span>Cardiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890047/cardiologist-geriatric-expertise/?query=fjwf&amp;rid=2201">Cardiologist-Geriatric Expertise</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1916046&amp;pubId=41289247&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6373973c9f179-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6373973c9f179-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6373973c9f179-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$725811103$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$725811103$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$725811103$--></div></div><div class="mlt-body"><!--?lit$725811103$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$725811103$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$725811103$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$725811103$-->Jun 27, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2401304?query=recirc_Semantic" target="_self">Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation</a></div><div class="mlt-article-authors"><!--?lit$725811103$-->S.P. Bhatt and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$725811103$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$725811103$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$725811103$-->Jul 20, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2303951?query=recirc_Semantic" target="_self">Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts</a></div><div class="mlt-article-authors"><!--?lit$725811103$-->S.P. Bhatt and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$725811103$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$725811103$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$725811103$-->May 19, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2504544?query=recirc_Semantic" target="_self">As-Needed Albuterol–Budesonide in Mild Asthma</a></div><div class="mlt-article-authors"><!--?lit$725811103$-->C. LaForce and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$725811103$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$725811103$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$725811103$-->Aug 17, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2307400?query=recirc_Semantic" target="_self">Hydrocortisone in Severe Community-Acquired Pneumonia</a></div><div class="mlt-article-authors"><!--?lit$725811103$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$725811103$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$725811103$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$725811103$-->Jun 02, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2203163?query=recirc_Semantic" target="_self">Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma</a></div><div class="mlt-article-authors"><!--?lit$725811103$-->A. Papi and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa1916046?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa1916046" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1916046.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa1916046"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa1911998" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Randomized Trial of Amoxicillin for Pneumonia in Pakistan</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa1915075" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Apgar Score and Risk of Neonatal Death among Preterm Infants</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1916046_f1.jpg"><img src="/cms/10.1056/NEJMoa1916046/asset/7146d115-33d7-4ddc-b19a-30372b6c95cb/assets/images/large/nejmoa1916046_f1.jpg" height="1816" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Screening, Randomization, and Treatment.</div><div class="notes"><div role="doc-footnote">Shown is the distribution of patients during screening, randomization, and treatment. The patients in the 320-μg–budesonide triple-therapy group received twice-daily doses of 320 μg of budesonide, 18 μg of glycopyrrolate, and 9.6 μg of formoterol fumarate; those in the 160-μg–budesonide triple-therapy group received twice-daily doses of 160 μg of budesonide, 18 μg of glycopyrrolate, and 9.6 μg of formoterol fumarate; those in the glycopyrrolate–formoterol group received twice-daily doses of 18 μg of glycopyrrolate and 9.6 μg of formoterol fumarate; and those in the budesonide–formoterol group received twice-daily doses of 320 μg of budesonide and 9.6 μg of formoterol fumarate. The intention-to-treat population included all patients who underwent randomization and received any amount of trial treatment. The modified intention-to-treat population included all patients in the intention-to-treat population with postrandomization data obtained before discontinuation of treatment. Any data collected after completion of, or discontinuation of, the assigned trial regimen was excluded from the modified intention-to-treat analysis but included in the intention-to-treat analysis. The safety population included all patients who underwent randomization, received any amount of treatment, and had a postrandomization safety assessment. Forty-four patients were excluded from all analysis populations because of overlapping treatment exposure from participating multiple times in the same study or participating concurrently in another study. An additional 20 patients were not included in the modified intention-to-treat population (8509 patients) because they had multiple enrollments, although with nonoverlapping treatment exposure (19 patients) or because of administrative reasons (1 patient); these patients were included in the safety population (8529 patients).</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1916046_f2.jpg"><img src="/cms/10.1056/NEJMoa1916046/asset/e929749f-b349-4e07-80fc-26f5fac1d565/assets/images/large/nejmoa1916046_f2.jpg" height="3438" width="2303" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Kaplan–Meier Estimates of the Cumulative Incidence of Moderate or Severe COPD Exacerbations and Death from Any Cause in Time-to-First-Event Analyses.</div><div class="notes"><div role="doc-footnote">Panel A shows the time to the first moderate or severe exacerbation of chronic obstructive pulmonary disease (COPD). The analysis was performed in the modified intention-to-treat population with the use of an efficacy estimand, which included only data obtained from patients while they were receiving a trial treatment. Panel B shows the time to death from any cause. The analysis was performed in the intention-to-treat population with the use of a treatment policy estimand, which included all observed data obtained from the patients regardless of whether they continued to receive their assigned treatment. The inset shows the same data on an enlarged y axis. Tick marks indicate the time of data censoring.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic Characteristics of the Patients at Baseline (Modified Intention-to-Treat Population).<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Efficacy End Points.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events during the 52-Week Treatment Period (Safety Population).<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/383/1" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 383 No. 1</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 02, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1911998" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Randomized Trial of Amoxicillin for Pneumonia in Pakistan</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">F. Jehan and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 02, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1915075" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Apgar Score and Risk of Neonatal Death among Preterm Infants</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">S. Cnattingius, S. Johansson, and N. Razaz</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 02, 2020</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1912400" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Amoxicillin for 3 or 5 Days for Chest-Indrawing Pneumonia in Malawian Children</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">A.-S. Ginsburg and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1916046%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1916046&amp;pubId=41289247&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1916046%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1916046&amp;pubId=41289247&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id08364113388767475" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6373973c9f179-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6373973c9f179-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6373973c9f179-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6373973c9f179-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6373973c9f179-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6373973c9f179-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6373973c9f179-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6373973c9f179-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6373973c9f179-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6373973c9f179-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d637396c2ef179',t:'MTc0OTUzMDY4OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d637396c2ef179&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><agx-yxloahindaju></agx-yxloahindaju><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa1916046?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=1-10"></script><iframe name="captureIFrame_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" data-transactionid="ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" id="captureIFrame_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" target="captureIFrame_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" name="capture_screen"><input id="capture_signIn_js_version_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" name="js_version"><input id="capture_signIn_transactionId_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" data-capturefield="undefined" value="ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" type="hidden" class="capture_transactionId_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" name="capture_transactionId"><input id="capture_signIn_form_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" name="form"><input id="capture_signIn_flow_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" name="flow"><input id="capture_signIn_client_id_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" name="client_id"><input id="capture_signIn_redirect_uri_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" name="redirect_uri"><input id="capture_signIn_response_type_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" name="response_type"><input id="capture_signIn_flow_version_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" name="flow_version"><input id="capture_signIn_settings_version_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" name="settings_version"><input id="capture_signIn_locale_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" name="locale"><input id="capture_signIn_recaptcha_version_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_ia69ildpgbh0of702ih4imgjh46c78i7l8zjuv5f" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>